91 results on '"Gaëlle Guettrot-Imbert"'
Search Results
2. Intrauterine fetal deaths related to antiphospholipid syndrome: a descriptive study of 65 women
- Author
-
Mériem Belhocine, Laetitia Coutte, Nicolas Martin Silva, Nathalie Morel, Gaëlle Guettrot-Imbert, Romain Paule, Claire Le Jeunne, Micaela Fredi, Michel Dreyfus, Jean-Charles Piette, Odile Souchaud-Debouverie, Catherine Deneux-Tharaux, Vassilis Tsatsaris, Emmanuelle Pannier, Véronique Le Guern, and Nathalie Costedoat-Chalumeau
- Subjects
Antiphospholipid syndrome ,Lupus ,Thrombosis ,Pregnancy ,Preeclampsia ,HELLP ,Diseases of the musculoskeletal system ,RC925-935 - Abstract
Abstract Objective Although one of the three obstetric manifestations of antiphospholipid syndrome (APS) is intrauterine fetal death (IUFD), little is known about it in this context. We report the first large series of patients with APS and IUFD. Methods We retrospectively analyzed the history and clinical data of women at four French hospitals. All had (1) APS diagnosis (Sydney criteria) and (2) IUFD at or after 10 weeks of gestation (weeks) between 2000 and 2016. Results The study included 65 women. Their median age at the index IUFD was 29 years (IQR 26–33); 38 (58%) were primigravidas. The index IUFD was the first APS clinical manifestation in 48 women (74%). Overall, 35% had a triple-positive antibody profile. IUFD occurred at a median gestational age of 24 weeks (IQR 18–27) and was associated with maternal obstetric complications in 16 women (25%), namely, preeclampsia (n = 12), hemolysis, elevated liver enzymes, and low platelet syndrome (HELLP) (n = 6), and/or placental abruption (n = 5). Half of the 50 women with available data had a small-for-gestational-age fetus. Overall, including during the follow-up period of 4 years (IQR 2–9), 28 women (43%) had at least one thrombosis, and 29% were diagnosed with systemic lupus erythematosus (SLE). Ultimately, 54 women (83%) had at least one live birth. Only one woman had three consecutive early miscarriages. Conclusion IUFD was most often the inaugural sign of APS. Of the APS classification criteria, IUFD, preeclampsia, and thromboses were common in this cohort, while the “3 consecutive early miscarriages” criterion was met only once. With treatment, most of the women successfully had at least one live birth.
- Published
- 2018
- Full Text
- View/download PDF
3. SLE-DAS in the First Trimester of Gestation Predicts Maternal Lupus Flares Later in Pregnancy
- Author
-
Maddalena Larosa, Nathalie Costedoat-Chalumeau, Gaëlle Guettrot-Imbert, Veronique Le Guern, Nathalie Morel, Diogo Jesus, Luca Iaccarino, Luís Inês, and Andrea Doria
- Subjects
systemic lupus erythematosus ,SLE-DAS ,pregnancy ,maternal flares ,adverse obstetrical outcome ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Introduction: Systemic Lupus Erythematosus (SLE) mainly occurs during childbearing age. Remission or low disease activity state (LDAS) before conception are recommended by experts to achieve a favourable lupus pregnancy outcome but little is known on the best way to evaluate remission or activity status during pregnancy.Objectives: We tested SLE-disease activity score (SLE-DAS) in the first trimester as predictor of maternal flares and obstetrical complications in 2nd and 3rd trimester in a cohort of SLE pregnant women.Patients and Methods: Inclusion criteria were: 1) women ≥ 18 years; 2) affected with SLE (SLICC 2012); 3) enrolled in two referral centers (Italy and France) 4) with an ongoing singleton pregnancy at 12 weeks (only one pregnancy per patient). Disease activity was assessed at first trimester of pregnancy, using SLE-pregnancy disease activity index (SLEPDAI) and retrospectively applying SLE-DAS. Maternal lupus flares at 2nd and 3rd trimester were defined by the SELENA-SLEDAI Flare Index (SFI). Adverse pregnancy outcome (APO) included: fetal and neonatal death, placental insufficiency with premature delivery
- Published
- 2021
- Full Text
- View/download PDF
4. Pregnancy outcomes in women with primary Sjögren's syndrome: an analysis of data from the multicentre, prospective, GR2 study
- Author
-
Grégoire Martin de Frémont, Nathalie Costedoat-Chalumeau, Estibaliz Lazaro, Rakiba Belkhir, Gaëlle Guettrot-Imbert, Nathalie Morel, Gaétane Nocturne, Anna Molto, Tiphaine Goulenok, Elisabeth Diot, Laurent Perard, Nicole Ferreira-Maldent, Maelle Le Besnerais, Nicolas Limal, Nihal Martis, Noémie Abisror, Odile Debouverie, Christophe Richez, Vincent Sobanski, François Maurier, Gaëtan Sauvetre, Hervé Levesque, Marie-Agnès Timsit, Nathalie Tieulié, Pauline Orquevaux, Boris Bienvenu, Matthieu Mahevas, Thomas Papo, Céline Lartigau-Roussin, Elodie Chauvet, Emilie Berthoux, Françoise Sarrot-Reynauld, Loïc Raffray, Marion Couderc, Nicolas Martin Silva, Noémie Jourde-Chiche, Nicolas Belhomme, Thierry Thomas, Vincent Poindron, Viviane Queyrel-Moranne, Juliette Delforge, Camille Le Ray, Emmanuelle Pannier, Xavier Mariette, Véronique Le Guern, Raphaèle Seror, Alexandra AUDEMARD-VERGER, Emmanuel AZZI, Béatrice BANNEVILLE, Antoine BAUDET, Constance BEAUDOUIN BAZIRE, Cristina BELIZNA, Alexandre Belot, Ygal BENHAMOU, Alice Berezné, Fanny BERNARD-GUERVILLY, Sabine BERTHIER, Holy BEZANAHARY, Lisa BIALE, Adrien BIGOT, Claire BLANCHARD-DELAUNAY, Anne CALAS, Julien CAMPAGNE, Pascal CATHEBRAS, Claire CAZALETS, Benjamin CHAIGNE, Olivia CHANDESRIS, Jérémy CHATELAIS, Emmanuel CHATELUS, Fleur COHEN, Bernard Combe, Céline COMPARON, Pascal COQUERELLE, Louise DAMIAN, Eric DAUGAS, Mathilde DE MENTHON, Claire DE MOREUIL, Estelle DELATTRE, Azeddine DELLAL, Catherine Deneux-Tharaux, Amélie DENIS, Camille DEPROUW, Emmanuelle DERNIS, Alban DEROUX, Sandra DESOUCHES, Philippe Dieudé, Guillaume DIREZ, Maxime Dougados, Marine DRIESSEN, Aurélie DU THANH, Laetitia DUNOGEANT, Cécile DURANT, Cécile-Audrey DUREL, Isabelle DURIEU, Florence EBOUE, Elisabeth Elefant, Olivier FAIN, Bruno FAUTREL, René-Marc FLIPO, Aline FRAZIER, Antoine FROISSART, Sophie GEORGIN-LAVIALLE, Elisabeth GERVAIS, Bertrand GODEAU, François Goffinet, Anne GOMPEL, Laure GOSSEC, Philippe GOUPILLE, Claire GRANGE, Constance GUILLAUD-DANIS, Eric HACHULLA, Sabine HOEFSLOOT, Aurélie HUMMEL, Patrick JEGO, Stéphanie JOBARD, Laurence JOSSELIN-MAHR, Marc LAMBERT, Vincent LANGLOIS, Delphine LARIVIERE, Claire LARROCHE, Augustin LATOURTE, Christian LAVIGNE, Thomas LE GALLOU, Gaëlle LEROUX, Jean Guillaume LETAROUILLY, Frédéric LIOTÉ, Laurence Loeuillet, Jonathan London, Valentine Loustau, Pierre LOZAC'H, Emmanuel MAHEU, Hélène MAILLARD, Hubert MAROTTE, Agathe MASSEAU, Arsène MEKINIAN, Sara Melboucy Belkhir, Corinne Miceli-Richard, Martin MICHAUD, Marc MICHEL, Olivier MORANNE, Chafika MORATI-HAFSAOUI, Guillaume MOULIS, Luc MOUTHON, Barbara NICOLAS, Jacky Nizard, Jérémy ORA, Rodérau OUTH, Elisabeth PASQUIER, Jean-Loup PENNAFORTE, Antoinette PERLAT, Hélène PETIT-BAUER, Evangeline PILLEBOUT, Jean-Maxime PIOT, Agnès PORTIER, Olivier Pourrat, Xavier PUECHAL, Gregory PUGNET, Manon REDONDIN, Alexis REGENT, Mélanie RORIZ, Laurent SAILLER, Léa SAVEY, Marc SCHERLINGER, Nicolas SCHLEINITZ, Jérémie Sellam, Loïc Sentilhes, Aude SERVAIS, Perrine SMETS, Christelle SORDET, Martin SOUBRIER, Katia STANKOVIC-STOJANOVIC, Geoffrey URBANSKI, Véronique VEIT, Emmanuelle WEBER, and Cécile YELNIK
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy - Published
- 2023
5. Characterisation of a high-risk profile for maternal thrombotic and severe haemorrhagic complications in pregnant women with antiphospholipid syndrome in France (GR2): a multicentre, prospective, observational study
- Author
-
Anne Murarasu, Gaëlle Guettrot-Imbert, Véronique Le Guern, Cécile Yelnik, Viviane Queyrel, Nicolas Schleinitz, Nicole Ferreira-Maldent, Elisabeth Diot, Geoffrey Urbanski, Emmanuelle Pannier, Estibaliz Lazaro, Odile Souchaud-Debouverie, Pauline Orquevaux, Nicolas Belhomme, Nathalie Morel, Elodie Chauvet, François Maurier, Maëlle Le Besnerais, Noemie Abisror, Tiphaine Goulenok, Françoise Sarrot-Reynauld, Alban Deroux, Elisabeth Pasquier, Claire de Moreuil, Holy Bezanahary, Laurent Pérard, Nicolas Limal, Vincent Langlois, Anne Calas, Bertrand Godeau, Christian Lavigne, Eric Hachulla, Fleur Cohen, Ygal Benhamou, Loïc Raffray, Mathilde de Menthon, Nathalie Tieulié, Vincent Poindron, Luc Mouthon, Maddalena Larosa, Elisabeth Eléfant, Loic Sentilhes, Anna Molto, Catherine Deneux-Tharaux, Nathalie Costedoat-Chalumeau, Emmanuel Azzi, Béatrice Banneville, Antoine Baudet, Constance Beaudouin-Bazire, Cristina Belizna, Rakiba Belkhir, Alice Berezne, Emilie Berthoux, Sabine Berthier, Lisa Biale, Boris Bienvenu, Claire Blanchard-Delaunay, Pascal Cathebras, Claire Cazalets, Benjamin Chaigne, Olivia Chandesris, Jérémy Chatelais, Emmanuel Chatelus, Pascal Coquerelle, Marion Couderc, Juliette Delforge, Amélie Denis, Sandra Desouches, Philippe Dieudé, Guillaume Direz, Marine Driessen, Aurélie Du Thanh, Laetitia Dunogeant, Cécile Durant, Isabelle Durieu, Marc Fabre, Olivier Fain, René-Marc Flipo, Aline Frazier, Antoine Froissart, Sophie Georgin-Lavialle, Elisabeth Gervais, Anne Gompel, Laure Gossec, Phillipe Goupille, Claire Grange, Constance Guillaud-Danis, Aurélie Hummel, Moez Jallouli, Patrick Jego, Stéphane Jobard, Laurence Josselin-Mahr, Noémie Jourde-Chiche, Anne-Sophie Korganow, Marc Lambert, Delphine Lariviere, Claire Larroche, Céline Lartigau-Roussin, Augustin Latourte, Thomas Le Gallou, Gaëlle Leroux, Hervé Levesque, Frédéric Lioté, Jonathan London, Valentine Loustau, Emmanuel Maheu, Matthieu Mahevas, Hélène Maillard, Xavier Mariette, Hubert Marotte, Nicolas Martin-Silva, Nihal Martis, Agathe Masseau, Arsène Mekinian, Sara Melboucy-Belkhir, Martin Michaud, Marc Michel, Chafika Morati-Hafsaoui, Jacky Nizard, Jérémy Ora, Jean-Loup Pennaforte, Antoinette Perlat, Hélène Petit Bauer, Evangeline Pillebout, Jean-Maxime Piot, Agnès Portier, Gregory Pugnet, Manon Redondin, Alexis Regent, Christophe Richez, Mélanie Roriz, Laurent Sailler, Gaëtan Sauvêtre, Léa Savey, Vincent Sobanski, Christelle Sordet, Martin Soubrier, Katia Stankovic Stojanovic, Thierry Thomas, Marie-Agnès Timsit, and Vassilis Tsatsaris
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy - Published
- 2022
6. Health Outcomes of 215 Mothers of Children With Autoimmune Congenital Heart Block: Analysis of the French Neonatal Lupus Syndrome Registry
- Author
-
Imene, Miniaoui, Nathalie, Morel, Kateri, Lévesque, Alice, Maltret, Marine, Driessen, Agathe, Masseau, Pauline, Orquevaux, Jean-Charles, Piette, Francois, Barriere, Jérome, Le Bidois, Sophie, Georgin-Lavialle, Gaëlle, Guettrot-Imbert, Véronique, Le Guern, Luc, Mouthon, Moez, Jallouli, Christophe, Deligny, Eric, Hachulla, Bénédicte, Romefort, Damien, Bonnet, and Nathalie, Costedoat-Chalumeau
- Subjects
Pregnancy ,Outcome Assessment, Health Care ,Infant, Newborn ,Humans ,Lupus Erythematosus, Systemic ,Female ,Registries ,Child ,Retrospective Studies ,Autoimmune Diseases - Abstract
Transplacental passage of maternal anti-SSA and anti-SSB antibodies, potentially associated with maternal autoimmune diseases, can cause neonatal lupus syndrome. Given the paucity of data in this setting, we report short- and long-term outcomes of mothers of offspring with congenital heart block (CHB).This retrospective study included anti-SSA/SSB antibody-positive mothers of fetuses with high-degree CHB and focused on their health status before pregnancy, at CHB diagnosis, and thereafter.We analyzed 215 women with at least 1 pregnancy with CHB. Prior to this diagnosis, only 52 (24%) mothers had been diagnosed with an autoimmune disease, mainly systemic lupus erythematosus (SLE; n = 26, 12%) and Sjögren syndrome (SS; n = 16, 7%). Six more were diagnosed with an autoimmune disease during the index pregnancy. Of the 157 mothers (73%) with no such diagnosis at childbirth, 77 (49%) developed one after a median follow-up of 11 years (range: 21 days to 54 years). By the end of follow-up, 135 women (63%) had an autoimmune disease diagnosis, mainly SLE (n = 54, 25%) and SS (n = 72, 33%). Three patients with SLE had renal involvement, and only 6 (3%) had required an immunosuppressive drug at any point. The symptoms best predicting autoimmune disease development were arthralgia and myalgia (One-quarter of the patients had an autoimmune disease diagnosis at the time of the fetal CHB diagnosis. Nearly half of those without an initial diagnosis progressed during follow-up, most without severe manifestations. Severe diseases such as lupus nephritis were rarely seen, and immunosuppressive drugs were rarely required.
- Published
- 2022
7. Consultation préconceptionnelle dans les maladies auto-immunes systémiques
- Author
-
Vassilis Tsatsaris, Véronique Le Guern, Gaëlle Guettrot-Imbert, Nathalie Costedoat-Chalumeau, and Anna Molto
- Subjects
030203 arthritis & rheumatology ,03 medical and health sciences ,0302 clinical medicine ,Rheumatology ,030212 general & internal medicine - Abstract
Resume Les maladies auto-immunes systemiques et les rhumatismes inflammatoires chroniques concernent frequemment des femmes jeunes en âge de procreer. Les grossesses sont generalement possibles et les risques fœto-maternels restent acceptables. Il est cependant indispensable que ces femmes soient informees qu’une grossesse pourra etre menee le plus souvent sans complications severes dans le cas ou la conception survient au cours d’une periode de remission. Le projet d’une grossesse doit donc etre aborde regulierement et sa planification est fortement recommandee. Celle-ci est realisee idealement au cours d’une consultation preconceptionnelle afin de rechercher d’eventuelles contre-indications (peu frequentes) et les facteurs de complications obstetricales (complication obstetricale anterieure, presence d’une biologie ou d’un syndrome des antiphospholipides, pathologie active en debut de grossesse, et insuffisance d’organe sequellaire d’une poussee anterieure) afin d’optimiser la prise en charge. Les complications obstetricales les plus frequentes sont les pertes fœtales et/ou les consequences d’une insuffisance placentaire. La presence d’anticorps anti-SSA et/ou anti-SSB expose a un risque faible de bloc auriculoventriculaire fœtal. Les traitements doivent etre adaptes avant la conception afin, d’une part, de limiter le risque de poussee en debut de grossesse et, d’autre part, d’interrompre ou remplacer les medicaments teratogenes. Enfin, le rythme et le lieu de la surveillance de cette future grossesse seront definis de maniere multidisciplinaire et expliques a la patiente a cette occasion.
- Published
- 2021
8. Pregnancy and neonatal outcomes in women with axial spondyloarthritis: pooled data analysis from the European Network of Pregnancy Registries in Rheumatology (EuNeP)
- Author
-
Yvette, Meissner, Anja, Strangfeld, Anna, Molto, Frauke, Forger, Marianne, Wallenius, Nathalie, Costedoat-Chalumeau, Hilde, Bjørngaard, Marion, Couderc, René-Marc, Flipo, Gaëlle, Guettrot-Imbert, Isabell, Haase, Bente, Jakobsen, Hege Suorza Svean, Koksvik, Christophe, Richez, Jérémie, Sellam, Anja, Weiß, Astrid, Zbinden, Rebecca, Fischer-Betz, Marie-Agnès, Timsit, Imagerie Moléculaire et Stratégies Théranostiques (IMoST), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA)
- Subjects
Adult ,Data Analysis ,Cesarean Section ,Tumor Necrosis Factor-alpha ,[SDV]Life Sciences [q-bio] ,Immunology ,Infant, Newborn ,Severity of Illness Index ,General Biochemistry, Genetics and Molecular Biology ,Treatment Outcome ,Rheumatology ,Pregnancy ,Spondylarthritis ,Immunology and Allergy ,Humans ,Premature Birth ,Female ,Spondylitis, Ankylosing ,Tumor Necrosis Factor Inhibitors ,Registries ,610 Medicine & health ,Axial Spondyloarthritis - Abstract
ObjectiveTo investigate outcome and course of pregnancies in women with axial spondyloarthritis (axSpA) in a pooled data analysis of pregnancy registries in rheumatology.MethodsProspectively followed women with axSpA, fulfilling ASAS classification criteria and for whom a pregnancy outcome was reported, were eligible for the analysis. Anonymised data of four registries was pooled. Rates of adverse pregnancy outcomes were calculated. Systemic inflammation, disease activity and treatment patterns with tumour necrosis factor inhibitor (TNFi) before, during and after pregnancy were analysed.ResultsIn a total of 332 pregnancies from 304 axSpA women, 98.8% of the pregnancies resulted in live birth. Mean maternal age was 31 years and disease duration 5 years. Most of these patients received pre-conception counselling (78.4%). Before pregnancy, 53% received TNFi treatment, 27.5% in first and 21.4% in third trimester. Pregnancy and neonatal outcomes were favourable with rates of 2.2% for pre-eclampsia, 4.9% for preterm birth, 3.1% for low birth weight and 9.5% for small for gestational age. Neonates were delivered by caesarean section in 27.7% of pregnancies, of which 47.4% were emergencies. Pooled mean CRP was 4 mg/L before conception peaking in the second trimester at 9.4 mg/L. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was below 4 at all time-points.ConclusionsPooled rates of most outcomes were better than what had been reported in the literature and within expected rates of those reported for the general population. Pre-conception counselling, planned pregnancies and a tight management in expert centres applying a tailored treatment approach may have contributed to the favourable pregnancy outcomes.
- Published
- 2022
9. Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case–control study with hydroxychloroquine blood-level analysis
- Author
-
Martine Mauget-Faÿsse, Thomas Papo, Camille Francès, Pascal Cohen, Nathalie Costedoat-Chalumeau, Nathalie Morel, J. Chezel, Elodie Bousquet, Moez Jallouli, François Chasset, Sawsen Salah, Luc Mouthon, Jean-Charles Piette, Véronique Le Guern, Alexis Régent, Tiphaine Lenfant, Gaëlle Leroux, Gaëlle Guettrot-Imbert, and Patrice Cacoub
- Subjects
Adult ,Male ,concentration ,medicine.medical_specialty ,hydroxychloroquine ,Renal function ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Retinal Diseases ,Rheumatology ,Internal medicine ,retinopathy ,medicine ,retinal toxicity ,Humans ,Lupus Erythematosus, Systemic ,Pharmacology (medical) ,030203 arthritis & rheumatology ,Univariate analysis ,Systemic lupus erythematosus ,Cumulative dose ,business.industry ,Case-control study ,Hydroxychloroquine ,lupus ,Odds ratio ,Middle Aged ,medicine.disease ,Antirheumatic Agents ,Case-Control Studies ,030221 ophthalmology & optometry ,Original Article ,Female ,business ,medicine.drug ,Retinopathy - Abstract
Objective HCQ is an essential medication in SLE, proven to lengthen survival and reduce flares. Its use, however, is limited by its rare but severe ophthalmological complications. Here, we aimed to analyse factors associated with HCQ retinopathy including HCQ blood levels. Methods This case–control study compared SLE patients with and without HCQ retinopathy, defined by abnormal results for at least two of the following ophthalmological tests: automated visual fields, spectral-domain optical coherence tomography (SD-OCT), multifocal electroretinogram (mfERG) and fundus autofluorescence. We compared clinical and laboratory findings to assess risk factors for HCQ retinopathy. Results The study included 23 patients with confirmed retinopathy (cases) and 547 controls. In the univariate analysis, age (P Conclusion SLE patients on HCQ should be closely monitored for retinopathy, especially those from the West Indies or sub-Saharan Africa, or with renal insufficiency, longer HCQ intake or a high cumulative dose. Although reducing the daily dose of HCQ in patients with persistently high HCQ blood levels seems logical, these concentrations were not associated with retinopathy in this study with controls adherent to treatment.
- Published
- 2020
10. Les auteurs
- Author
-
Alexandra Benachi, Dominique Luton, Laurent Mandelbrot, Olivier Picone, Hélène Affres, Nadine Ajzenberg, Laurence Amar, Pascale Amate, Djillali Annane, Rana Aoun, Elie Azria, Rakiba Belkhir, Ivan Berlin, Jacques Bernuau, Emmanuel Boleslawski, Claire Bonneau, Marie Bornes, Yoram Bouhnik, Corinne Bouteloup, Elisabeth Bouvet, Dominique Brémond-Gignac, Arnaud Bresset, Florence Bretelle, Léopoldine Bricaire, Marie Bruyère, Julie Carrara, Pierre-François Ceccaldi, Philippe Chanson, Sophie Chauvet, Bernard Clair, Élodie Clouqueur, Sarah Cohen, Chloé Comarmond-Ortoli, Jacqueline Conard, Sophie Conquy, Henri Copin, Anne-Gaël Cordier, Sophie Cordiez, Sarah Coscas, Nathalie Costedoat-Chalumeau, Emile Daraï, Amélie Delabaere, Philippe Deruelle, Marc Dommergues, Anne-Sophie Ducloy-Bouthors, Caroline Dubertret, Hubert Ducou Le Pointe, Bénédicte Dumont, Lise Duranteau, Elisabeth Elefant, Nejla Essafi, Hervé Fernandez, Julia Filippova, Renato Fior, Michael Frank, Jean-Baptiste de Fréminville, Diane Friedman, Frédéric Galacteros, Denis Gallot, Gilles Garcia, Jean-Yves Gauvrit, Anne Gervais, Robert Girot, Bertrand Godeau, Gilles Grangé, Dominique Grenet, Lionel Groussin-Rouiller, Gaëlle Guettrot-Imbert, Stéphanie Guillet, Anoosha Habibi, Smail Hadj-Rabia, Olivier Hermine, Véronique Houfflin-Debarge, Marie Houllier, Lucile Houyel, Marc Humbert, Laurence Iserin, Bernard Iung, Xavier Jaïs, Bérangère Joly, Guillaume Jondeau, Jean-Emmanuel Kahn, Gilles Kayem, Hawa Keita, Valentin Keller, Magalie Ladouceur, Cécile Lavenu-Bombled, Hélène Legardeur, Véronique Le Guern, Claude Lejeune, Claire Le Jeunne, null Lous, null Ray, Aurélien Lorthioir, Lynda Manamani-Bererhi, Isabelle Marie, Grégoire Martin de Frémont, Sophie Matheron, Amandine Maulard, Nadia Merbai, Emmanuel Messas, Sandra de Miranda, Anna Molto, Stéphanie Morgant, Simon Msika, Sophie Nebout, Jacky Nizard, Roseline d'Oiron, Violaine Ozenne, Gabriel Perlemuter, Sandrine Perol, Franck Perrotin, Brigitte Perrouin-Verbe, Edith Peynaud-Debayle, Violaine Peyronnet, Henri-Jean Philippe, Clément Picard, Geneviève Plu-Bureau, Laura Polivka, Brigitte Raccah-Tebeka, Emmanuelle de Raucourt, Jean-Antoine Ribeil, Thomas Ronzière, Valérie Roussel-Robert, Aude Rossi, Lucia Rugeri, David Saadoun, Lise Selleret, Pierre Sellier, Marie-Victoire Sénat, Raphaèle Seror, Damien Subtil, Camille Taillé, Sarah Tebeka, Denis Therby, Ngoc-Tram Tô, Bertrand de Toffol, Nathalie Trillot, Vassilis Tsatsaris, Géraud Tuyeras, Mathieu Uzzan, Morgane Valentin, David Vandendriessche, Roxane Vanspranghels-Gibert, Eric Verspyck, Aurélie Vincent-Rohfritsch, Sandra Vukusic, Bernard Wechsler, Norbert Winer, and Jacques-François Young
- Published
- 2022
11. Evaluation of lupus anticoagulant, damage, and remission as predictors of pregnancy complications in systemic lupus erythematosus: the French GR2 study
- Author
-
Maddalena, Larosa, Véronique, Le Guern, Gaëlle, Guettrot-Imbert, Nathalie, Morel, Noémie, Abisror, Chafika, Morati-Hafsaoui, Pauline, Orquevaux, Elisabeth, Diot, Andrea, Doria, Françoise, Sarrot-Reynauld, Nicolas, Limal, Viviane, Queyrel, Odile, Souchaud-Debouverie, Laurent, Sailler, Maëlle, Le Besnerais, Tiphaine, Goulenok, Anna, Molto, Emmanuelle, Pannier-Metzger, Loic, Sentilhes, Luc, Mouthon, Estibaliz, Lazaro, Nathalie, Costedoat-Chalumeau, and Cécile, Yelnik
- Subjects
Male ,Placenta ,Infant, Newborn ,Pregnancy Outcome ,Antiphospholipid Syndrome ,Pregnancy Complications ,Rheumatology ,Pregnancy ,Lupus Coagulation Inhibitor ,Humans ,Lupus Erythematosus, Systemic ,Pharmacology (medical) ,Female ,Prospective Studies ,Retrospective Studies - Abstract
Objectives The specific roles of remission status, lupus low disease activity state (LLDAS), and damage accrual on the prognosis of pregnancies in women with SLE are unknown. We analysed their impact on maternal flares and adverse pregnancy outcomes (APOs). Methods We evaluated all women (≥18 years) with SLE enrolled in the prospective GR2 study with an ongoing singleton pregnancy at 12 weeks (one pregnancy/woman). Several sets of criteria were used to define remission, disease activity and damage. APOs included: foetal/neonatal death, placental insufficiency with preterm delivery and small-for-gestational-age birth weight. First trimester maternal and disease features were tested as predictors of maternal flares and APOs. Results The study included 238 women (98.3% on hydroxychloroquine (HCQ)) with 230 live births. Thirty-five (14.7%) patients had at least one flare during the second/third trimester. At least one APOs occurred in 34 (14.3%) women. Hypocomplementemia in the first trimester was the only factor associated with maternal flares later in pregnancy (P=0.02), while several factors were associated with APOs. In the logistic regression models, damage by SLICC-Damage Index [odds ratio (OR) 1.8, 95% CI: 1.1, 2.9 for model 1 and OR 1.7, 95% CI: 1.1, 2.8 for model 2] and lupus anticoagulant (LA, OR 4.2, 95% CI: 1.8, 9.7 for model 1; OR 3.7, 95% CI: 1.6, 8.7 for model 2) were significantly associated with APOs. Conclusion LA and damage at conception were predictors of APOs, and hypocomplementemia in the first trimester was associated with maternal flares later in pregnancy in this cohort of pregnant patients mostly with well-controlled SLE treated with HCQ. Trial registration ClinicalTrials.gov, https://clinicaltrials.gov, NCT02450396.
- Published
- 2021
12. P79 Predictors of adverse neonatal outcome during the pregnancy of women with antiphospholipid syndrome in the French GR2 prospective study
- Author
-
P. Orquevaux, O. Souchaud-Debouverie, Estibaliz Lazaro, François Maurier, Véronique Le Guern, Alban Deroux, Gaëlle Guettrot-Imbert, Maëlle Le Besnerais, Catherine Deneux-Tharaux, Nathalie Costedoat-Chalumeau, A. Murarasu, and Patrick Jego
- Subjects
Lupus anticoagulant ,medicine.medical_specialty ,Pregnancy ,Placental abruption ,HELLP syndrome ,Obstetrics ,business.industry ,medicine.disease ,Preeclampsia ,Antiphospholipid syndrome ,medicine ,Small for gestational age ,business ,Prospective cohort study - Abstract
Introduction Data about the predictors of adverse neonatal outcome in pregnant women with antiphospholipid syndrome (APS) are sparse. The main study on this subject is the prospective American study PROMISSE on 144 carriers of antiphospholipid antibodies.1 We report the first results of the French study, GR2. Methods Inclusion criteria were: (1) an ongoing pregnancy at 12 weeks of gestation (WG), (2) conceived before May 2018, (3) of a woman with APS.2 Exclusion criteria were proteinuria (ratio >1 g/g), serum creatinine >100 µmol/L, and multifetal pregnancy. The composite primary outcome included an intrauterine fetal death (IUFD), a neonatal death, placental insufficiency (fetal growth restriction, preeclampsia, HELLP syndrome, and/or placental abruption) leading to a delivery ≤34 WG, and/or a small for gestational age (SGA) ≤3rd percentile. Results We analysed 119 pregnancies in 119 patients: 53% thrombotic and 47% obstetric only APS; 60% had lupus anticoagulant (LA) and 26% associated SLE. Treatment included aspirin (99%), heparin (98%, in the therapeutic range for 50%), and hydroxychloroquine (62%). The primary outcome was observed in 14% of pregnancies: 3% IUFD, 8% delivery ≤34WG due to placental insufficiency and/or 5% of SGA (and no neonatal death). It was observed in 20% of the pregnancies with LA compared with 7% for women negative for LA (P=0.096). This outcome did not differ according to anticardiolipin or antiβ2GP1 antibody status, or prior thrombosis (14%, versus 14% for women with only obstetric APS). There was a trend toward more adverse neonatal outcomes in case of prior arterial thrombosis (29% versus 12%, P=0.07). The rate of adverse neonatal outcomes did not differ among the women with or without associated SLE (29% versus 26%, P=0.77). In multivariate analysis, independent features associated with pregnancy failure were: in a serological model, LA positive status (ORa=8.5, 95%CI[1.0–71.5]) and in a serological and clinical model, ‘non-white’ skin colour (ORa=6.1, 95%CI[1.1–34.7]). Conclusion The rate of adverse neonatal outcomes tended to be lower than in the PROMISSE study (14% versus 19%), although the women included here were theoretically more severe (definite APS). One potential explanation might be that our patients were all treated. In keeping with the PROMISSE study, LA and skin colour were the main predictors of neonatal outcome. Acknowledgement Fondation pour la Recherche Medicale (M2R201806006403) References Lockshin MD, et al. Arthritis Rheum. 2012; 64;2311–8. Miyakis S, et al. J Thromb Haemost. 2006; 4 ;295–306. Andreoli L, et al. Ann Rheum Dis. 2017; 76; 476–85.
- Published
- 2020
13. Bleeding complications and antithrombotic treatment in 264 pregnancies in antiphospholipid syndrome
- Author
-
Jane E. Salmon, V. Le Guern, P.Y. Hatron, D W Branch, Nathalie Morel, Lisa R. Sammaritano, David Launay, J-L Bacri, Gaëlle Guettrot-Imbert, N. Costedoat-Chalumeau, Carl A. Laskin, Cécile Yelnik, Marc Lambert, Eric Hachulla, Marta M. Guerra, and Elodie Drumez
- Subjects
Adult ,medicine.medical_specialty ,Time Factors ,Blood Loss, Surgical ,Postoperative Hemorrhage ,Risk Assessment ,03 medical and health sciences ,Antithrombotic treatment ,0302 clinical medicine ,Fibrinolytic Agents ,Rheumatology ,Pregnancy ,Risk Factors ,Antiphospholipid syndrome ,Internal medicine ,Antithrombotic ,medicine ,Humans ,Blood Transfusion ,In patient ,Prospective Studies ,Retrospective Studies ,030203 arthritis & rheumatology ,Lupus anticoagulant ,Aspirin ,030219 obstetrics & reproductive medicine ,Cesarean Section ,business.industry ,Postpartum Hemorrhage ,Anticoagulants ,Heparin ,Heparin, Low-Molecular-Weight ,Antiphospholipid Syndrome ,medicine.disease ,United States ,Treatment Outcome ,Drug Therapy, Combination ,Female ,France ,business ,Platelet Aggregation Inhibitors ,medicine.drug - Abstract
Purpose The purpose of this study was to evaluate the safety of antithrombotic treatments prescribed during pregnancy in patients with antiphospholipid syndrome (APS). Methods This international, multicenter study included two cohorts of patients: a retrospective French cohort and a prospective US cohort (PROMISSE study). Inclusion criteria were (1) APS (Sydney criteria), (2) live pregnancy at 12 weeks of gestation (WG) with (3) follow-up data until six weeks post-partum. According to APS standard of care, patients were treated with aspirin and/or low-molecular weight heparin (LMWH) at prophylactic (pure obstetric APS) or therapeutic doses (history of thrombosis). Major bleeding was defined as abnormal blood loss during the pregnancy and/or post-partum period requiring intervention for hemostasis or transfusion, or during the peripartum period greater than 500 mL and/or requiring surgery or transfusion. Other bleeding events were classified as minor. Results Two hundred and sixty-four pregnancies (87 prospectively collected) in 204 patients were included (46% with history of thrombosis, 23% with associated systemic lupus). During pregnancy, treatment included LMWH ( n = 253; 96%) or low-dose aspirin ( n = 223; 84%), and 215 (81%) patients received both therapies. The live birth rate was 89% and 82% in the retrospective and prospective cohorts, respectively. Adverse pregnancy outcomes occurred in 28% of the retrospective cohort and in 40% of the prospective cohort. No maternal death was observed in either cohort. A combined total of 45 hemorrhagic events (25%) occurred in the retrospective cohort, but major bleeding was reported in only six pregnancies (3%). Neither heparin nor aspirin alone nor combined therapy increased the risk of hemorrhage. We also did not observe an increased rate of bleeding in the case of a short interval between last LMWH (less than 24 hours) or aspirin (less than five days) doses and delivery. Only emergency Caesarean section was significantly associated with an increased risk of bleeding (odds ratio (OR) 5.03 (1.41–17.96); p=.016). In the prospective cohort, only one minor bleeding event was reported (vaginal bleeding). Conclusion Our findings support the safety of antithrombotic therapy with aspirin and/or LMWH during pregnancy in high-risk women with APS, and highlight the need for better treatments to improve pregnancy outcomes in APS. PROMISSE Study ClinicalTrials.gov identifier: NCT00198068.
- Published
- 2018
14. Incidence, risk factors, and mortality of neonatal and late-onset dilated cardiomyopathy associated with cardiac neonatal lupus
- Author
-
Christophe Deligny, Francois Barriere, P. Orquevaux, Eric Hachulla, Olivier Fain, Delphine Le Mercier, Philippe Ravaud, Jérôme Le Bidois, Bénédicte Romefort, Sophie Georgin-Lavialle, Claire Le Jeunne, Gaëlle Guettrot-Imbert, Francois Sassolas, Elisabeth Villain, Luc Mouthon, Nathalie Costedoat-Chalumeau, Laurent Fermont, Alice Maltret, Quentin Hauet, Mohamed Hamidou, Jean-Charles Piette, Gabriel Baron, Kateri Levesque, Damien Bonnet, Arnaud Theulin, and Nathalie Morel
- Subjects
Adult ,Cardiomyopathy, Dilated ,Male ,Cardiac function curve ,medicine.medical_specialty ,Adolescent ,030204 cardiovascular system & hematology ,complex mixtures ,Pericardial effusion ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Internal medicine ,Humans ,Lupus Erythematosus, Systemic ,Medicine ,Registries ,cardiovascular diseases ,Age of Onset ,Mortality ,Child ,Retrospective Studies ,030203 arthritis & rheumatology ,business.industry ,Incidence ,Mortality rate ,Infant, Newborn ,Infant ,Endocardial fibroelastosis ,Dilated cardiomyopathy ,musculoskeletal system ,medicine.disease ,In utero ,Child, Preschool ,cardiovascular system ,Cardiology ,Female ,Age of onset ,Cardiology and Cardiovascular Medicine ,business ,Complication ,Follow-Up Studies - Abstract
Background Dilated cardiomyopathy (DCM), a well-known complication of cardiac neonatal lupus, is associated with high mortality rate. Its risk factors remain unclear. Methods We analyzed occurrence of postnatal DCM among children with high-degree congenital heart block (CHB) and mothers with anti-SSA and/or anti-SSB antibodies. Results Among 187 neonates with CHB, 35 (18.8%, one missing data) had DCM and 22 (11.8%) died during a median follow-up of 7years [range: birth–36years]. On multivariate analysis, factors associated with postnatal DCM were in utero DCM ( P =0.0199; HR=3.13 [95% CI: 1.20–8.16]), non-European origin ( P =0.0052; HR=4.10 [95% CI: 1.81–9.28]) and pacemaker implantation ( P =0.0013; HR=5.48 [95% CI: 1.94–15.47]). Postnatal DCM could be categorized in two subgroups: neonatal DCM (n=13, diagnosed at a median age of 0day [birth–4days]) and late-onset DCM (n=22, diagnosed at a median age of 15.2months [3.6months–22.8years]). Factors associated with neonatal DCM were in utero DCM, hydrops, endocardial fibroelastosis and pericardial effusion, whereas those associated with late-onset DCM were non-European origin, in utero mitral valve insufficiency, and pacemaker implantation. Fluorinated steroids showed no protective effect against late-onset DCM ( P =0.27; HR=1.65 [95% CI: 0.63–4.25]). Probability of survival at 10years was 23.1% for newborns diagnosed neonatally with DCM, 53.9% for those who developed late-onset DCM, and 98.6% for those without DCM. Conclusion Neonatal and late-onset DCM appear to be two different entities. None of the known risk factors associated with neonatal DCM predicted late-onset DCM. Long-term follow-up of cardiac function is warranted in all children with CHB.
- Published
- 2017
15. In VitroFertilization in 37 Women with Systemic Lupus Erythematosus or Antiphospholipid Syndrome: A Series of 97 Procedures
- Author
-
Agathe Masseau, P. Orquevaux, Véronique Le Guern, Jean-Charles Piette, D. Vauthier, Jean-Loup Pennaforte, Gaëlle Guettrot-Imbert, Du Le Thi Huong, Patrice Cacoub, Nathalie Morel, Nathalie Costedoat-Chalumeau, Bertrand Wechsler, and Vanessa Gayet
- Subjects
030203 arthritis & rheumatology ,Infertility ,medicine.medical_specialty ,Pregnancy ,030219 obstetrics & reproductive medicine ,Systemic lupus erythematosus ,Obstetrics ,business.industry ,Immunology ,Ovarian hyperstimulation syndrome ,Hydroxychloroquine ,Premature ovarian insufficiency ,medicine.disease ,Surgery ,03 medical and health sciences ,0302 clinical medicine ,Rheumatology ,Antiphospholipid syndrome ,medicine ,Immunology and Allergy ,Polyarthritis ,skin and connective tissue diseases ,business ,medicine.drug - Abstract
Objective.To compile and assess data about complication and success rates forin vitrofertilization (IVF) of women with systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS). To date, such data are sparse.Methods.This retrospective study described women with SLE and/or APS who have had at least 1 IVF cycle.Results.Thirty-seven women with SLE (n = 23, including 8 with antiphospholipid antibodies), SLE with APS (n = 4), or primary APS (n = 10) underwent 97 IVF procedures. For 43% of cases, the infertility was female in origin, for 19% male, 14% mixed, and 24% unexplained. No women had premature ovarian insufficiency because of cyclophosphamide. Median age at IVF was 34 years (range 26–46). The median number of IVF cycles was 2.6 (1–8). Patients were treated with hydroxychloroquine (72%), steroids (70%), azathioprine (3%), aspirin (92%), and/or low molecular weight heparin (62%). There were 27 (28%) pregnancies, 23 live births among 26 neonates (3 twin pregnancies), 2 miscarriages, and 2 terminations for trisomy 13 and 21. Six spontaneous pregnancies occurred during the followup. Finally, 26 women (70%) delivered at least 1 healthy child. Complications occurred in or after 8 IVF cycles (8%): SLE flares in 4 (polyarthritis in 3 and lupus enteritis in 1) and thromboembolic events in 4 others. One SLE flare was the first sign of previously undiagnosed SLE. Poor treatment adherence was obvious in 2 other flares and 2 thromboses. No ovarian hyperstimulation syndrome was reported.Conclusion.These preliminary results confirm that IVF can be safely and successfully performed in women with SLE and/or APS.
- Published
- 2017
16. Description of 214 cases of autoimmune congenital heart block: Results of the French neonatal lupus syndrome
- Author
-
Kateri Levesque, Nathalie Morel, Alice Maltret, Gabriel Baron, Agathe Masseau, Pauline Orquevaux, Jean-Charles Piette, Francois Barriere, Jérome Le Bidois, Laurent Fermont, Olivier Fain, Arnaud Theulin, Francois Sassolas, Philippe Pezard, Zahir Amoura, Gaëlle Guettrot-Imbert, Delphine Le Mercier, Sophie Georgin-Lavialle, Christophe Deligny, Eric Hachulla, Luc Mouthon, Philippe Ravaud, Elisabeth Villain, Damien Bonnet, Nathalie Costedoat-Chalumeau, Holy Bezanahary, Boris Bienvenu, Gilles Blaison, Philippe Blanche, Bernard Bonnotte, Pascal Cathebras, Christine Christides, Fleur Cohen, Laurence Cohen, Edouard Devaud, Elisabeth Diot, Pierre Duhaut, Yves Dulac, Bertrand Godeau, Véronique Gournay, Céline Gronier, Loïc Guillevin, Mohamed Hamidou, Julien Haroche, Gilles Hayem, François Heitz, Richard Isnard, Moez Jallouli, Anne-Sophie Korganow, Claire Le Jeunne, François Lhote, Hugues Lucron, Jean-René Lusson, Suzel Magnier, Jacques Ninet, Nicolas Pangaud, Thomas Papo, Jean-Luc Pellegrin, Jean Loup Pennaforte, Jacques Pouchot, Françoise Sarrot-Reynauld, Nicolas Schleinitz, Pascal Seve, Bertrand Stos, Denis Vital-Durand, and Bertrand Wechsler
- Subjects
Pacemaker, Artificial ,medicine.medical_specialty ,Pediatrics ,Fetus ,Pregnancy ,Multivariate analysis ,Heart block ,business.industry ,Immunology ,Retrospective cohort study ,Dilated cardiomyopathy ,medicine.disease ,Prosthesis Implantation ,Heart Block ,Treatment Outcome ,In utero ,Internal medicine ,medicine ,Cardiology ,Humans ,Lupus Erythematosus, Systemic ,Immunology and Allergy ,Gestation ,business - Abstract
Cardiac neonatal lupus syndrome is due to anti-SSA or SSB antibodies and mainly includes congenital heart block (CHB) and dilated cardiomyopathy (DCM). Its optimal management is still debated. We report a large series of autoimmune high degree CHB.Inclusion criteria in this retrospective study were fetuses or neonates with high-degree CHB associated with maternal anti-SSA/SSB antibodies.214 CHB were included: 202 detected in utero at a median term of 23 weeks' gestation (WG) [range 16 to 39 WG] and 12 neonatal cases diagnosed at a median age of 0 days [range birth to 8 days]. The 214 cases of CHB included 202 (94.4%) third-degree CHB, 8 (3.7%) second-degree CHB, and 4 (1.9%) intermittent CHB. In multivariate analysis, the factors associated with feto-neonatal deaths (15.7%) were hydrops (p0.001; hazard ratio [HR] 12.4 [95% confidence interval (95%CI) 4.7-32.7]) and prematurity (p=0.002; HR 17.1 [95%CI 2.8-103.1]). During a median follow-up of 7 years [birth to 36 years], 148 of 187 children born alive (79.1%) had a pacemaker, 35 (18.8%, one missing data) had DCM, and 22 (11.8%) died. In multivariate analysis, factors associated with child death were in utero DCM (p=0.0157; HR 6.37 [95%CI: 1.25-32.44]), postnatal DCM (p0.0001; HR 227.58[95%CI: 24.33-2128.46]) and pacemaker implantation (p=0.0035; HR 0.11[95%CI: 0.02-0.51]). The use of fluorinated steroids was neither associated with survival nor with regression of 2nd degree CHB.In this second largest series of CHB, we confirm some of the previous results. We were unable to find data supporting the routine use of in utero fluorinated steroids.
- Published
- 2015
17. Dépistage et prise en charge du risque cardiovasculaire au cours du lupus systémique : élaboration de recommandations pour la pratique clinique, à partir d’une analyse de la littérature et de l’avis d’experts
- Author
-
Philippe Remy, V. Baudouin, M. Chauchard, T. Papo, A. Ghali, Laurent Arnaud, A.S. Korganow, P. Gobert, O. Meyer, A. Viau Brabant, P. Marianetti-Guingel, Viviane Queyrel, N. Martin Silva, Aurélie Hummel, T. Kwon, N. Magy-Bertrand, A. Le Quellec, Noémie Jourde-Chiche, Jean-Loup Pennaforte, V. Le Guern, Thierry Martin, Bernard Bonnotte, Sandrine Morell-Dubois, Jean-François Viallard, M. Hamidou, Nicolas Limal, Makoto Miyara, E. Hachulla, Eric Daugas, A. Chaib, Cristina Belizna, F. Boumedine, Zahir Amoura, Julien Haroche, Denis Wahl, I. Raymond, Brigitte Bader-Meunier, J. Sibilia, Karim Sacre, Guillaume Gondran, E. Bruckert, Laurent Chiche, Jeannot Schmidt, K. Polomat, Baptiste Hervier, Jacques Ninet, Daniel Adoue, Jacques Pourrat, Alexis Mathian, and Gaëlle Guettrot-Imbert
- Subjects
Gynecology ,medicine.medical_specialty ,business.industry ,Cardiovascular risk factors ,Gastroenterology ,Internal Medicine ,medicine ,business - Abstract
Resume Propos L’objectif de ce travail etait de proposer des recommandations relatives aux modalites de depistage et de prise en charge des facteurs de risque cardiovasculaire au cours du lupus systemique. Methodes Trente-neuf experts internistes, rhumatologues ou nephrologues francais, membres du reseau des centres de reference et de competence du lupus systemique ont pris part a un vote visant a retenir ou non des recommandations preparees par un groupe de travail a partir d’une revue de la litterature. Resultats Les experts ont souligne que les facteurs de risque cardiovasculaires modifiables doivent etre recherches au moins annuellement au cours du lupus systemique. La prescription d’une statine en prevention primaire depend du taux de LDL-cholesterol et du nombre de facteurs de risque cardiovasculaires, en considerant le lupus systemique comme un facteur de risque cardiovasculaire supplementaire. En prevention secondaire, les experts s’accordent a proposer une cible de LDL-cholesterol Conclusions Ces recommandations vont permettre d’ameliorer et d’homogeneiser la pratique des differents medecins francais impliques dans la prise en charge du lupus systemique. L’actualisation de ces recommandations pourra etre ulterieurement envisagee, en fonction des nouvelles donnees publiees.
- Published
- 2015
18. Pathologies hépatiques et grossesse
- Author
-
S Hillaire, V. Le Guern, Gaëlle Leroux, Aurélie Plessier, Gaëlle Guettrot-Imbert, C. Delluc, and Nathalie Costedoat-Chalumeau
- Subjects
medicine.medical_specialty ,Pregnancy ,Cirrhosis ,medicine.diagnostic_test ,business.industry ,Gastroenterology ,Jaundice ,medicine.disease ,Acute fatty liver of pregnancy ,Hyperemesis gravidarum ,Liver disease ,Internal medicine ,Internal Medicine ,Medicine ,medicine.symptom ,business ,Liver function tests ,Cholestasis of pregnancy - Abstract
Liver disease can be observed in pregnant women whether or not related to pregnancy. Liver disorders can be revealed by pruritus, vomiting, jaundice or abnormal liver blood tests during pregnancy. These liver manifestations can lead to the diagnosis of liver disease specifically associated to pregnancy as intrahepatic pregnancy, intrahepatic cholestasis of pregnancy, Hyperemesis gravidarum, acute fatty liver of pregnancy and preeclampsia-induced liver injury. Pregnancy may also be a risk factor for other liver diseases coincident with pregnancy as viral hepatitis, thrombosis, drug toxicity or gallstone. Finally, pre-existing liver disease must be taken into account given the risk of fœto-maternal transmission risk as well as the risk of decompensation of underlying cirrhosis secondary to the hemodynamic changes caused by pregnancy. The aim of this revue is to perform an update on the various situations that can be observed, the principles of management of these liver diseases, in order to reduce the risk of complications and to ensure the best maternal and fetal prognosis.
- Published
- 2015
19. Lupus systémique et syndrome des antiphospholipides : comment prendre en charge la grossesse ?
- Author
-
J.C. Piette, Nathalie Costedoat-Chalumeau, Nathalie Morel, V. Le Guern, Vassilis Tsatsaris, D. Vauthier, Emmanuelle Pannier, and Gaëlle Guettrot-Imbert
- Subjects
medicine.medical_specialty ,Population ,Complications obstétricales ,Anticorps anti-SSA ,Systemic lupus erythematosus ,Obstetrics and gynaecology ,Antiphospholipid syndrome ,immune system diseases ,Pregnancy ,medicine ,Internal Medicine ,Medical history ,Preconception counseling ,education ,skin and connective tissue diseases ,Adverse obstetrical outcome ,Fetus ,education.field_of_study ,Obstetrics ,business.industry ,Gastroenterology ,medicine.disease ,Review article ,Grossesse ,Lupus systémique ,business ,Consultation pré-conceptionnelle ,Syndrome des antiphospholipides ,Anti-SSA antibodies - Abstract
RésuméLa survenue d’une grossesse au cours du lupus systémique est une situation fréquente qui reste associée à une morbi-mortalité maternelle et fœtale plus importante que dans la population générale. Les complications incluent les poussées lupiques, les complications obstétricales (pertes fœtales, retard de croissance in utero, pré-éclampsie, prématurité) et le lupus néonatal. Une biologie ou un syndrome des antiphospholipides augmente nettement le risque de complications obstétricales. L’amélioration de la prise en charge de ces grossesses est conditionnée par leur planification systématique, idéalement au cours d’une consultation pré-conceptionnelle, et par une prise en charge multidisciplinaire avec une collaboration étroite entre interniste/rhumatologue, obstétricien et anesthésiste. L’absence d’activité du lupus, un traitement compatible avec la grossesse adapté aux antécédents et aux risques ainsi qu’une surveillance régulière sont les principaux éléments permettant une issue favorable à ces grossesses à risque. Cette revue a pour objectif de proposer une mise au point sur la prise en charge actuelle de la grossesse au cours du lupus systémique ou du syndrome des antiphospholipides afin de limiter le risque de complications et d’assurer le meilleur pronostic tant maternel que fœtal.AbstractPregnancy in systemic lupus erythematosus patients is a common situation that remains associated with higher maternal and fetal mortality/morbidity than in the general population. Complications include lupus flares, obstetrical complications (fetal loss, in utero growth retardation, prematurity) and neonatal lupus syndrome. The association with antiphospholipid antibodies or antiphospholipid syndrome increases the risk of obstetrical complications. Improving the care of these pregnancies depends upon a systematic pregnancy planning, ideally during a preconception counseling visit and a multidisciplinary approach (internist/rheumatologist, obstetrician and anesthetist). The absence of lupus activity, the use of appropriate medications during pregnancy adjusted to the patient's medical history and risk factors, and a regular monitoring are the best tools for a favorable outcome for these high-risk pregnancies. The aim of this review article is to perform an update on the medical care of pregnancy in systemic lupus erythematosus or antiphospholipid syndrome to reduce the risk of complications and to ensure the best maternal and fetal prognosis.
- Published
- 2015
- Full Text
- View/download PDF
20. « Lupus néonatal » : revue de la littérature
- Author
-
Chantal Brouzes, D. Le Mercier, Bettina Bessières, Nathalie Costedoat-Chalumeau, Alice Maltret, Sophie Georgin-Lavialle, V. Le Guern, Nathalie Morel, K. Levesque, Elisabeth Villain, Gaëlle Guettrot-Imbert, and J. Le Bidois
- Subjects
Pediatrics ,medicine.medical_specialty ,Myocarditis ,medicine.diagnostic_test ,business.industry ,Gastroenterology ,Undifferentiated connective tissue disease ,Dilated cardiomyopathy ,Endocardial fibroelastosis ,Hydroxychloroquine ,medicine.disease ,Connective tissue disease ,Internal Medicine ,medicine ,Neonatal lupus erythematosus ,business ,Fetal echocardiography ,medicine.drug - Abstract
Neonatal lupus syndrome is associated with transplacental passage of maternal anti-SSA/Ro and anti-SSB/La antibodies. Children display cutaneous, hematological, liver or cardiac features. Cardiac manifestations include congenital heart block (CHB); endocardial fibroelastosis and dilated cardiomyopathy. The prevalence of CHB in newborns of anti-Ro/SSA positive women with known connective tissue disease is between 1 and 2% and the risk of recurrence is around 19%. Skin and systemic lesions are transient, whereas CHB is definitive and associated with significant morbidity and a mortality of 18%. A pacemaker must be implanted in 2/3 of cases. Myocarditis may be associated or appear secondly. Mothers of children with CHB are usually asymptomatic or display Sjogren's syndrome or undifferentiated connective tissue disease. In anti-Ro/SSA positive pregnant women, fetal echocardiography should be performed at least every 2 weeks from the 16th to 24th week gestation. An electrocardiogram should be performed for all newborn babies. The benefit of fluorinated corticosteroid therapy for CHB detected in utero remains unclear. Maternal use of hydroxychloroquine may be associated with a decreased recurrent CHB risk in a subsequent offspring. A prospective study is actually ongoing to confirm these findings.
- Published
- 2015
21. Fécondation in vitro au cours du lupus érythémateux systémique ou du syndrome des antiphospholipides : mise au point
- Author
-
D. Vauthier, V. Le Guern, Jean-Loup Pennaforte, J.C. Piette, P. Orquevaux, N. Costedoat-Chalumeau, Gaëlle Guettrot-Imbert, Agathe Masseau, Nathalie Morel, B. Wechsler, D. Boutin, and V. Gayet
- Subjects
Gynecology ,education.field_of_study ,medicine.medical_specialty ,In vitro fertilisation ,Lupus Flare ,business.industry ,media_common.quotation_subject ,medicine.medical_treatment ,Population ,Gastroenterology ,Ovarian hyperstimulation syndrome ,Fertility ,medicine.disease ,Thrombosis ,Induction ovulation ,immune system diseases ,Antiphospholipid syndrome ,Internal Medicine ,Medicine ,skin and connective tissue diseases ,business ,education ,media_common - Abstract
Fertility is not impaired in systemic lupus erythematosus or antiphospholipid syndrome, but, similarly to the general population, these patients may undergo in vitro fertilization. This type of treatment increases the risk of lupus flare, thrombosis, and ovarian hyperstimulation syndrome. This review will focus on in vitro fertilization in systemic lupus erythematosus or antiphospholipid syndrome. Literature data are relatively scant with only 3 reported studies. The first one included 17 patients and 63 cycles of induction ovulation/in vitro fertilization leading to 25 % of lupus flare, no thrombosis, and 3 % of ovarian hyperstimulation syndrome. The second study included 10 patients and 40 cycles of in vitro fertilization showing 31 % of lupus flare, no thrombosis and no ovarian hyperstimulation syndrome. The last one included 34 patients and 83 procedures of in vitro fertilization leading to 8 % of flares, 5 % of thrombosis and no ovarian hyperstimulation syndrome. Interestingly, in this last study, half of the complications were explained by poor adherence to treatment. These data are reassuring but it is important to remember that in vitro fertilization should be scheduled and carefully supervised in the same way as the high-risk pregnancies occurring in these patients.
- Published
- 2015
22. Hydroxychloroquine: A multifaceted treatment in lupus
- Author
-
Nathalie Costedoat-Chalumeau, Véronique Le Guern, Nathalie Morel, Bertrand Dunogué, and Gaëlle Guettrot-Imbert
- Subjects
Oncology ,medicine.medical_specialty ,Side effect ,Medication Adherence ,Pathogenesis ,Antimalarials ,Retinal Diseases ,Internal medicine ,Diabetes mellitus ,medicine ,Humans ,Lupus Erythematosus, Systemic ,skin and connective tissue diseases ,Lupus erythematosus ,Systemic lupus erythematosus ,business.industry ,Interferon-alpha ,Hydroxychloroquine ,General Medicine ,medicine.disease ,Toll-Like Receptor 7 ,Antirheumatic Agents ,Toll-Like Receptor 9 ,Immunology ,business ,Complication ,Biomarkers ,Dyslipidemia ,Half-Life ,medicine.drug - Abstract
The efficacy of antimalarials, especially hydroxychloroquine (HCQ), in preventing systemic lupus erythematosus (SLE) flares is well demonstrated. However, many studies show that the percentage of SLE patients treated with HCQ remains low. By blocking the toll-like receptor 7 and 9 in plasmacytoid dendritic cells, HCQ inhibits interferon-alpha production which plays a crucial role in SLE pathogenesis. In addition to reducing damage accrual in SLE patients, HCQ appears to protect against the occurrence of diabetes, thrombotic events, and dyslipidemia. As a consequence, some studies have suggested that HCQ, which is inexpensive, has a protective effect on survival in SLE patients. Thanks to the pharmacokinetic properties of HCQ (long half-life) and to the availability of its blood assay, very low or undetectable blood HCQ concentrations are a valuable marker of non-adherence to treatment, thus adding a new benefit to HCQ prescriptions. The main side effect of HCQ is retinal toxicity. This complication is very rare, but may be potentially severe, thus requiring regular screening. Retinal toxicity remains the only absolute contra-indication of HCQ in adult SLE patients. Other contra-indications are few and rare. During pregnancy and breast-feeding, HCQ continuation is not only allowed but recommended. In conclusion, the risk/benefit ratio of HCQ is excellent. Many now believe that all SLE patients should be offered this treatment.
- Published
- 2014
23. Les glomérulopathies associées aux néoplasies myéloprolifératives
- Author
-
A. Tiple, P. Deteix, O. Aumaître, M. Hermet, K. El Karoui, M. André, Marion Rabant, J.-O. Bay, Jean-Louis Kémény, A. Bardy, and Gaëlle Guettrot-Imbert
- Subjects
Gastroenterology ,Internal Medicine - Abstract
Resume Propos Les neoplasies myeloproliferatives (NMP) sont des desordres hematologiques caracterises par l’expansion clonale d’une ou plusieurs lignees medullaires. Les complications renales sont rares et se manifestent principalement par un tableau d’insuffisance renale aigue. L’atteinte glomerulaire est quant a elle exceptionnelle Methodes Nous decrivons ici une serie retrospective multicentrique de huit cas de glomerulopathie (GP) associee a une NMP Resultats Toutes les GP se sont manifestees par une proteinurie majeure regulierement accompagnee d’un syndrome nephrotique et d’œdemes des membres inferieurs. L’histologie est surtout caracterisee par des lesions de hyalinose segmentaire et focale associee a une augmentation de la cellularite mesangiale. La physiopathologie reste non elucidee mais il semble que le platelet-derived growth factor (PDGF) et le transforming growth factor-β (TGF-β), qui jouent un role central dans les NMP, puissent etre impliques. La majorite des patients ont ete traites par blocage du systeme renine-angiotensine. Mais l’evolution se fait generalement vers l’insuffisance renale chronique Conclusion La surveillance de la proteinurie au cours du suivi des NMP permettrait un diagnostic plus precoce de cette complication. Des etudes complementaires a plus grande echelle sont necessaires afin, d’une part, de preciser les mecanismes physiopathologiques mis en jeu et, d’autre part, de codifier la prise en charge specifique de ces complications
- Published
- 2014
24. La consultation préconceptionnelle
- Author
-
V. Le Guern, Nathalie Costedoat-Chalumeau, and Gaëlle Guettrot-Imbert
- Subjects
Gynecology ,medicine.medical_specialty ,business.industry ,Gastroenterology ,Internal Medicine ,medicine ,Pre-pregnancy counseling ,business - Abstract
Resume La consultation preconceptionnelle est une des cles du succes de la grossesse chez les femmes atteintes d’une maladie auto-immune ou systemique, notamment un lupus systemique ou un syndrome des antiphospholipides. Cette consultation, idealement a proposer a toutes les patientes suivies pour une maladie systemique, permet de donner le feu vert pour debuter une grossesse ou d’expliquer pourquoi ce projet doit etre retarde, d’anticiper certains problemes, de proposer une information complete au couple, d’organiser une prise en charge multidisciplinaire, d’adapter les traitements et de verifier la validite des vaccinations. La generalisation de ce type de consultation devrait permettre de reduire les risques fœto-maternels chez ces jeunes femmes, et d’ameliorer encore le pronostic de ces grossesses.
- Published
- 2015
25. Péricardite récidivante : traquer le mésotheliome péricardique primitif
- Author
-
Olivier Aumaître, Gaëlle Guettrot-Imbert, Marc André, J.-L. Kemeny, I. Delèvaux, P. Smets, and M. Hermet
- Subjects
Gynecology ,medicine.medical_specialty ,business.industry ,Gastroenterology ,Internal Medicine ,medicine ,Recurrent pericarditis ,business - Abstract
Resume Introduction L’exploration des pericardites recidivantes permet la decouverte d’une etiologie specifique dans seulement 15 a 20 % des cas. Le mesotheliome pericardique primitif (MPP) est l’une d’entre elles et reste rare. Son diagnostic n’est etabli avec certitude que dans 10 a 20 % des cas avant autopsie. Il repose sur des arguments a la fois histologiques et immunohistochimiques. La mediane de survie apres diagnostic est d’environ six mois mais semble s’ameliorer avec le pemetrexed. Observation Nous rapportons l’observation d’une femme de 64 ans chez laquelle des biopsies pericardiques repetees ont ete necessaires pour l’obtention du diagnostic de MPP ; l’histologie initiale etant une hyperplasie mesotheliale benigne. Conclusion Cette observation souligne la necessite de repeter les biopsies pericardiques en cas d’evolution defavorable d’une pericardite.
- Published
- 2013
26. Maladie fibrosclérosante à IgG4
- Author
-
Olivier Aumaître, Marion Hermet, Jean-Louis Kémény, Gaëlle Guettrot-Imbert, Isabelle Delèvaux, and Marc André
- Subjects
Blood level ,integumentary system ,biology ,business.industry ,fungi ,General Medicine ,medicine.disease ,Pathophysiology ,Subclass ,Corticosteroid therapy ,Fibrosis ,parasitic diseases ,Immunology ,biology.protein ,Medicine ,IgG4-related disease ,Antibody ,skin and connective tissue diseases ,business ,Autoimmune pancreatitis - Abstract
Key points IgG4 related disease (IgG4 RD) was first reported as autoimmune pancreatitis then it was established as a systemic disorder characterised by high blood level of IgG4 and fibrosis with rich plasmocytes IgG4+ in almost all organs. IgG4 RD is very sensitive to corticosteroid therapy. IgG4 RD has a high prevalence in eastern countries. Numerous articles on this topic are published and new diagnostic criteria are regularly established. The autoimmune or allergic mechanism of IgG4 RD is still a matter of debate. Interestingly, IgG4 subclass of antibody has anti-inflammatory features. IgG4 RD is not yet very well characterised in western countries. Whether IgG4 is involved in IgG4 RD, pathophysiology is to be defined. IgG4 RD spontaneously regresses in some cases so indications of treatment are not already well clear.
- Published
- 2012
27. Is IgG4-Related Disease a Cause of Xerostomia? A Cohort Study of 60 Patients
- Author
-
Gaëlle Guettrot-Imbert, M. Hermet, G. Le Guenno, I. Delèvaux, P. Déchelotte, M. André, O. Aumaître, Jean-Louis Kémény, A. Tridon, and Martin Soubrier
- Subjects
medicine.medical_specialty ,Pathology ,lcsh:Diseases of the musculoskeletal system ,Article Subject ,Immunology ,Disease ,Gastroenterology ,stomatognathic system ,Rheumatology ,Internal medicine ,Sicca syndrome ,parasitic diseases ,Biopsy ,Medicine ,skin and connective tissue diseases ,integumentary system ,biology ,medicine.diagnostic_test ,business.industry ,fungi ,medicine.disease ,Dry mouth ,Clinical Study ,biology.protein ,IgG4-related disease ,lcsh:RC925-935 ,Antibody ,medicine.symptom ,business ,Immunostaining ,Cohort study - Abstract
Objective. Immunoglobulin-G4-(IgG4-) related disease (IgG4 RD) is a fibrosing process characterized by a significant infiltration of IgG4-secreting plasma cells. IgG4 RD can affect almost all organs including salivary glands. Whether IgG4 RD plays a role in the development of sicca syndrome and particularly dry mouth syndrome remains to be investigated.Methods. We conducted a monocentric cohort study for two years to search for IgG4 RD features in patients with dry mouth syndrome using immunostainings of labial salivary gland specimens with anti-IgG4 antibody.Results. Among 60 patients presenting with dry mouth syndrome who underwent labial salivary gland biopsy, 18 showed positive immunostaining with the anti-IgG4 antibody including 4 patients with typical systemic IgG4 RD. Five also fulfilled criteria for Sjögren's syndrome.Conclusion. These findings suggest that clinical forms of IgG4 RD salivary involvement without salivary swelling may occur. This salivary involvement is probably overlooked in everyday practice and could represent a mild form of IgG4 RD.
- Published
- 2012
28. F-18 FDG-PET/CT in aseptic abscesses with recurrent febrile abdominal pain
- Author
-
Marc André, Zahir Amoura, Olivier Aumaître, Julien Haroche, Gilles Grimon, Gaëlle Guettrot-Imbert, Stefano Possenti, Antony Kelly, Jacques Ninet, and Frédéric Charlotte
- Subjects
Adult ,Male ,Fluorine Radioisotopes ,medicine.medical_specialty ,Abdominal pain ,Abdominal Abscess ,Fever ,medicine.drug_class ,Anti-Inflammatory Agents ,Spleen ,Antibodies, Monoclonal, Humanized ,Fluorodeoxyglucose F18 ,Recurrence ,medicine ,Adalimumab ,Humans ,Abscess ,Cyclophosphamide ,medicine.diagnostic_test ,business.industry ,Liver Diseases ,Hereditary Autoinflammatory Diseases ,Gastroenterology ,Antibodies, Monoclonal ,Middle Aged ,medicine.disease ,Abdominal Pain ,medicine.anatomical_structure ,Positron emission tomography ,Positron-Emission Tomography ,Prednisone ,Abdomen ,Corticosteroid ,Female ,Lymph Nodes ,Radiology ,Aseptic processing ,medicine.symptom ,Nuclear medicine ,business ,Immunosuppressive Agents ,medicine.drug - Abstract
Mendelian and complex autoinflammatory disorders frequently manifest as recurrent abdominal pain and fever. Diagnosis may be difficult and scant data are available about the interest of 2-deoxy-2-[18F]fluoro-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) in such conditions, particularly aseptic abscesses (AA).We analyzed five cases of AA in which FDG-PET/CT was performed at diagnosis (n = 2) and after a suspected relapse (n = 5). Follow-up FDG-PET/CT was performed in two patients 9 days and 6 weeks after the initiation of oral corticosteroids.FDG-PET/CT showed intense uptake foci in the abdominal lymph nodes (n = 4), liver (n = 2) and spleen (n = 4) before treatment. A marked metabolic response was observed while patients were being treated. In a relapsing patient with abdominal pain but no raised CRP, although CT scan was unchanged, abnormal uptake of FDG was observed. By contrast, some lesions previously observed on CT scan displayed no fixation on new FDG-PET/CT and were suggestive of sequelae in three patients.Although nonspecific, FDG-PET/CT may be an interesting tool for the diagnosis and management of recurrent and febrile abdominal pain in AA. At the time of relapse, it can differentiate between a sequela of previous flares and a new localization. It can be used for whole-body screening to look for other asymptomatic disease localizations.
- Published
- 2010
29. Adénopathies prétragiennes liées à Bartonella henselae
- Author
-
M. Hermet, O. Aumaître, Gaëlle Guettrot-Imbert, M. André, C. Makarawiez, S. Trouillier, and A.-S. Resseguier
- Subjects
Gynecology ,medicine.medical_specialty ,Pathology ,Bartonella henselae ,biology ,business.industry ,Gastroenterology ,Internal Medicine ,medicine ,business ,biology.organism_classification - Abstract
Resume Introduction La maladie des griffes du chat se manifeste sous la forme d’adenites evoluant dans la majorite des cas spontanement vers la guerison. Nous rapportons deux observations de maladie des griffes du chat avec atteinte pretragienne survenant chez les sujets immunocompetents. Observations Observation 1 : un homme de 28 ans consultait pour une tumefaction cervicale gauche d’apparition recente, avec secondairement une paralysie faciale peripherique et une cytolyse hepatique. Les serologies des hepatites virales, EBV, CMV, VIH, toxoplasmose etaient negatives. La biopsie exerese ganglionnaire retrouvait une lymphadenite granulomateuse et la PCR Bartonella henselae etait positive. Sous doxycycline pendant trois mois, associe a de la rifampicine pendant 15 jours, l’atteinte hepatique disparaissait et la paralysie faciale regressait partiellement. Observation 2 : un homme de 17 ans consultait pour une tumefaction parotidienne droite associee a des adenopathies cervicales posterieures, avec fievre et sueurs profuses. Un volumineux ganglion pretragien droit avec remaniement necrotique etait visible au scanner. La PCR B. henselae sur le liquide de cytoponction ganglionnaire etait positive. L’evolution etait favorable apres un drainage chirurgical et l’echec d’un traitement par macrolides. Conclusion La localisation pretragienne de la maladie des griffes du chat est rare. Cette topographie doit etre connue et necessiter la recherche d’un contact avec un chat apres exclusion d’une localisation tumorale parotidienne, d’un lymphome ou d’une tuberculose. Le diagnostic repose sur la PCR B. henselae . L’evolution est souvent spontanement favorable mais un traitement chirurgical peut etre necessaire.
- Published
- 2013
30. Pregnancy and contraception in systemic and cutaneous lupus erythematosus
- Author
-
V. Le Guern, Camille Francès, Gaëlle Guettrot-Imbert, Nathalie Morel, Nathalie Costedoat-Chalumeau, and Geneviève Plu-Bureau
- Subjects
medicine.medical_specialty ,Pregnancy, High-Risk ,Population ,Dermatology ,Preconception Care ,Ultrasonography, Prenatal ,03 medical and health sciences ,0302 clinical medicine ,immune system diseases ,Antiphospholipid syndrome ,Pregnancy ,medicine ,Lupus Erythematosus, Cutaneous ,Humans ,Lupus Erythematosus, Systemic ,Medical history ,skin and connective tissue diseases ,education ,Fetal Death ,030203 arthritis & rheumatology ,education.field_of_study ,030219 obstetrics & reproductive medicine ,Systemic lupus erythematosus ,Fetal Growth Retardation ,Obstetrics ,business.industry ,Postpartum Period ,Infant, Newborn ,Anticoagulants ,medicine.disease ,Antiphospholipid Syndrome ,Prognosis ,Pregnancy Complications ,Contraception ,Premature birth ,Echocardiography ,Immunology ,Antibodies, Antiphospholipid ,Premature Birth ,Female ,business ,Postpartum period - Abstract
A causal link has long been described between estrogen and systemic lupus erythematosus activity. Contraceptive and pregnancy management is now common for lupus patients, but pregnancy continues to be associated with higher maternal and fetal mortality/morbidity in systemic lupus erythematosus patients than among the general population. Potential complications include lupus flares, obstetric complications (fetal loss, in utero growth retardation, premature birth) and neonatal lupus syndrome. Association with antiphospholipid antibodies or antiphospholipid syndrome increases the risk of obstetric complications. Anti-SSA and/or anti-SSB antibodies put fetuses at risk for neonatal lupus. Improving the outcome of such pregnancies depends upon optimal systematic planning of pregnancy at a preconception counseling visit coupled with a multidisciplinary approach. Absence of lupus activity, use of appropriate medication during pregnancy based on the patient's medical history and risk factors, and regular monitoring constitute the best tools for achieving a favorable outcome in such high-risk pregnancies. The aim of this review is to provide an update on the management of contraception and pregnancy in systemic lupus erythematosus, cutaneous lupus and/or antiphospholipid syndrome in order to reduce the risk of complications and to ensure the best maternal and fetal prognosis.
- Published
- 2014
31. Liste des collaborateurs
- Author
-
Hélène Affres, Laurence Amar, Pascale Amate, Djillali Annane, Elie Azria, Alexandra Benachi, Ivan Berlin, Jacques Bernuau, Guillaume Bobrie, Emmanel Boleslawski, Claire Bonneau, Marie Bornes, Yoram Bouhnik, Corinne Bouteloup, Elisabeth Bouvet, Dominique Brémond-Gignac, Arnaud Bresset, Florence Bretelle, Léopoldine Bricaire, Marie Bruyere, Pierre-François Ceccaldi, Philippe Chanson, Sophie Chauvet, Bernard Clair, Élodie Clouqueur, Sarah Cohen, Jacqueline Conard, Cloé Comarmond, Sophie Conquy, Henri Copin, Anne-Gaël Cordier, Sophie Cordiez, Nathalie Costedoat-Chalumeau, Emile Daraï, Amélie Delabaere, Philippe Deruelle, Marc Dommergues, Marie Dreyfus, Caroline Dubertret, Lê Thi Huong Du-Boutin, Guillaume Ducarme, Anne-Sophie Ducloy-Bouthors, Hubert Ducou Le Pointe, Lise Duranteau, Fadi Fakhouri, Hervé Fernandez, Hélène Ferrand, Julia Filippova, Renato Fior, Michael Frank, Diane Friedman, Frédéric Galacteros, Denis Gallot, Gilles Garcia, Jean-Yves Gauvrit, Anne Gervais, Robert Girot, Bertrand Godeau, Gilles Grangé, Dominique Grenet, Lionel Groussin, Gaëlle Guettrot-Imbert, Anoosha Habibi, Smail Hadj-Rabia, Olivier Hermine, Véronique Houfflin-Debarge, Lucile Houyel, Justine Hugon-Rodin, Marc Humbert, Laurence Iserin, Bernard Iung, Xavier Jaïs, Bérangère Joly, Guillaume Jondeau, Jean-Emmanuel Kahn, Gilles Kayem, Hawa Keita, Valentin Keller, Magalie Ladouceur, Hélène Legardeur, Véronique Le Guern, Claude Lejeune, Claire Le Jeunne, Camille Le Ray, Dominique Luton, Lynda Manamani-Bererhi, Laurent Mandelbrot, Isabelle Marie, Sophie Matheron, Amandine Maulard, Nadia Merbai, Emmanuel Messas, Sandra De Miranda, Stéphanie Morgant, Simon Msika, Sophie Nebout, Sophie Nedellec, Jacky Nizard, Roseline d'Oiron, Violaine Ozenne, Gabriel Perlemuter, Brigitte Perrouin-Verbe, Franck Perrotin, Edith Peynaud-Debayle, Henri-Jean Philippe, Clément Picard, Olivier Picone, Marie Pigeyre, Pierre-François Plouin, Geneviève Plu-Bureau, Laura Polivka, Patrice Poulain, Marie de Pradier, Brigitte Raccah-Tebeka, Jean-Antoine Ribeil, Roman Rouzier, Thomas Ronziere, Aude Rossi, David Saadoun, Lise Selleret, Pierre Sellier, Marie-Victoire Sénat, Damine Subtil, Camille Taillé, Denis Therby, Ngoc-Tram Tô, Bertrand de Toffol, Nathalie Trillot, Vassilis Tsatsaris, Géraud Tuyeras, Morgane Valentin, Anne Vambergue, David Vandendriessche, Eric Verspyck, Aurélie Vincent-Rohfritsch, Marie-Catherine Voltzenlogel, Sandra Vukusic, Bernard Wechsler, Norbert Winer, and Jacques-François Young
- Published
- 2014
32. Maladies de système
- Author
-
N. Costedoat-Chalumeau, Vassilis Tsatsaris, Gaëlle Guettrot-Imbert, and V. Le Guern
- Subjects
business.industry ,Medicine ,business - Published
- 2014
33. Bénéfice et risque du traitement antithrombotique au cours de 264 grossesses évolutives chez des patientes atteintes d’un syndrome des antiphospholipides
- Author
-
Jane E. Salmon, M.M. Guerrra, J-L Bacri, Nathalie Morel, Gaëlle Guettrot-Imbert, Cécile Yelnik, N. Costedoat-Chalumeau, E. Hachulla, Martin F. Lambert, P.Y. Hatron, D. Launay, and V. Le Guern
- Subjects
Gastroenterology ,Internal Medicine - Abstract
Introduction La prise en charge de la grossesse au cours du syndrome des antiphospholipides (SAPL) est complexe et reste principalement empirique. L’objectif de notre etude etait d’evaluer le benefice et les risques des traitements antithrombotiques conventionnels prescrits lors de la grossesse dans une large cohorte de patientes atteintes d’un SAPL. Notre objectif secondaire etait d’identifier les facteurs de risques associes a un pronostic obstetrical defavorable. Patients et methodes Dans cette etude multicentrique internationale, les grossesses evolutives a 12 semaines d’amenorrhees (SA) survenues chez des patientes ayant un SAPL connu (criteres de Sydney), ont ete incluses et suivies jusqu’a six semaines du post-partum. Les donnees ont ete recueillies (1) a partir d’une etude prospective multicentrique americaine et (2) a partir des bases de donnees de quatre centres hospitaliers francais. Les complications obstetricales attribuables au SAPL etaient definies par la survenue : (i) d’une mort fœtale in utero (MFIU) ou (ii) d’un retard de croissance intra-uterin ≤ 5e percentile (RCIU) ou (iii) d’un accouchement premature avant 36 SA sans autre cause retrouvee ou (iv) d’une pre-eclampsie et/ou d’un syndrome HELLP. Resultats Un total de 264 grossesses (chez 204 patientes) ont ete incluses, dont 87 prospectivement. Dans 51 % des grossesses, les patientes avaient une forme thrombotique de SAPL et dans 25 % des cas, les patientes avaient un lupus systemique associe. L’heparine a ete prescrite au cours de 96 % des grossesses (n = 253) et l’aspirine faible dose dans 84 % des grossesses (n = 223). Quatre-vingt-six pour cent des grossesses ont donne naissance a un enfant vivant, sans aucun deces maternel. Les complications obstetricales du SAPL ont ete observees dans 32 % des cas, principalement au cours du 2nd trimestre de grossesse : 11 % de MFIU, 11 % de RCIU, 18 % de pre-eclampsie/HELLP/prematurite. Au cours de ces 264 grossesses, 13 thromboses maternelles ont ete observees (6 thromboses veineuses profondes, 1 embolie pulmonaire, 2 necroses hemorragiques des surrenales, 3 syndromes catastrophiques des antiphospholipides, 1 infarctus splenique) et 46 evenements hemorragiques, avec un saignement majeur dans 2 % des cas (3 hemorragies de la delivrance, 2 reprises chirurgicales pour hematome intra-abdominal, 1 embolisation de l’artere uterine). En analyse multivariee, les facteurs de risque de complication obstetricale etaient un index de masse corporel eleve et la presence d’un anticoagulant circulant lupique. A l’inverse, la prescription d’aspirine (mais pas celle d’heparine) etait associee a une diminution significative de ce risque (odds ratio : 0,34 ; 95 % IC : 0,15–0,78 ; p = 0,01). Le risque hemorragique n’etait pas associe a la prescription d’aspirine ou d’heparine, ni a la duree d’arret de l’aspirine avant l’accouchement (donnees non disponibles dans la cohorte americaine). Conclusion Dans cette large cohorte, nous avons observe un taux eleve de complications obstetricales du SAPL malgre une prise en charge therapeutique conforme aux recommandations. Nos resultats suggerent un benefice clinique important de l’aspirine sans augmentation du risque hemorragique et sont donc en faveur de sa prescription tout au long de la grossesse chez ces patientes.
- Published
- 2016
34. Efficacy of Il-1β blockade in refractory aseptic abscesses syndrome
- Author
-
A. Bardy, Marc André, Olivier Aumaître, and Gaëlle Guettrot-Imbert
- Subjects
medicine.medical_specialty ,business.industry ,Tumor Necrosis Factor-alpha ,Anti-Inflammatory Agents, Non-Steroidal ,Antibodies, Monoclonal ,Rheumatology ,Abscess ,Receptors, Tumor Necrosis Factor ,Surgery ,Blockade ,Refractory ,Internal medicine ,Anesthesia ,Immunoglobulin G ,Orthopedic surgery ,medicine ,Humans ,Female ,Aseptic processing ,business ,Glucocorticoids - Abstract
(2014). Efficacy of Il-1β blockade in refractory aseptic abscesses syndrome. Modern Rheumatology: Vol. 24, No. 1, pp. 217-219.
- Published
- 2013
35. Study of anti-Müllerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide
- Author
-
Nathalie Morel, Du Le Thi Huong Boutin, Véronique Le Guern, Jean-Emmanuel Kahn, Zahir Amoura, Jean-Charles Piette, Zeina Chakhtoura, Marie-Laure Tanguy, Jean-Marc Lacorte, Dominique Farge, Gaëlle Guettrot-Imbert, Aurélien Delluc, Damien Sène, Anne Bachelot, Philippe Touraine, Jean-Robert Harlé, Françoise Sarrot-Reynauld, Pascale Ghillani-Dalbin, Anne Gompel, Elisabeth Vidal, Lionel Galicier, Karim Sacre, Pierre Duhaut, Olivier Lambotte, Salim Trad, Jacques Pourrat, O. Aumaître, Nathalie Costedoat-Chalumeau, Camille Francès, Centre d'études européennes de Sciences Po ( CEE ), Sciences Po, Endocrinologie moléculaire, Institut National de la Santé et de la Recherche Médicale ( INSERM ), Laboratoire d'Immunochimie ( APHP PSL Immuno ), Assistance publique - Hôpitaux de Paris (AP-HP), Service de médecine interne [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], Immunité et Infection, Université Pierre et Marie Curie - Paris 6 ( UPMC ) -IFR113-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service d'immunologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ) -Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Service de médecine interne, hôpital Gabriel-Montpied, CHU Clermont-Ferrand, Service de Néphrologie - Immunologie Clinique [Toulouse], CHU Toulouse [Toulouse]-Hôpital de Rangueil, CHU Toulouse [Toulouse]-PRES Université de Toulouse, Laboratoire d'Immunologie ( EA 2686 ), Université de Lille, Droit et Santé, Immunologie, dermatologie, oncologie, Oncodermatologie, immunologie et cellules souches cutanées ( DIO U976 ), Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service de Dermatologie [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Tenon [APHP], Anthropologie bio-culturelle, Droit, Ethique et Santé ( ADES ), Aix Marseille Université ( AMU ) -EFS ALPES MEDITERRANEE-Centre National de la Recherche Scientifique ( CNRS ), service de médecine interne, Hôpital de Bicêtre, Centre de Référence des microangiopathies thrombotiques ( CNR-MAT ), service d'hématologie-CHU Saint-Antoine [APHP], Service de Médecine Interne, Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP]-Université Paris Descartes - Paris 5 ( UPD5 ), Service de Médecine interne A et polyclinique médicale [CHU Limoges], CHU Limoges, Homéostasie Cellulaire et Pathologies ( HCP ), Université de Limoges ( UNILIM ) -CHU Limoges-Génomique, Environnement, Immunité, Santé, Thérapeutique ( GEIST FR CNRS 3503 ), Clinique de médecine interne, Université Joseph Fourier - Grenoble 1 ( UJF ) -CHU Grenoble, Service d'endocrinologie gynécologique, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôtel-Dieu-Université Paris Descartes - Paris 5 ( UPD5 ), Centre national de référence des angioedemes, Service de biostatistiques et information médicale [CHU Pitié-Salpêtrière], Department of Endocrinology and Reproductive Medicine, CHU Pitié-Salpêtrière [APHP]-Centre de Référence des Maladies Endocriniennes rares de la croissance et des maladies gynécologiques rares, Université Pierre et Marie Curie - Paris 6 ( UPMC ), Immunologie - Immunopathologie - Immunothérapeutique ( I3 ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Département de Médecine Interne et Pneumologie [Brest] ( DMIP - Brest ), Centre Hospitalier Régional Universitaire de Brest ( CHRU Brest ), Groupe d'Etude de la Thrombose de Bretagne Occidentale ( GETBO ), Université de Brest ( UBO ), Centre d'Investigation Clinique ( CIC - Brest ), Université de Brest ( UBO ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre d'études européennes et de politique comparée (Sciences Po, CNRS) (CEE), Sciences Po (Sciences Po)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR113-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Médecine Interne [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-PRES Université de Toulouse, Laboratoire d'Immunologie (EA 2686), Oncodermatologie, immunologie et cellules souches cutanées (IDO (U976 / UMR_S 976)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Tenon [AP-HP], Anthropologie bio-culturelle, Droit, Ethique et Santé (ADES), Aix Marseille Université (AMU)-EFS ALPES MEDITERRANEE-Centre National de la Recherche Scientifique (CNRS), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5), Homéostasie Cellulaire et Pathologies (HCP), Université de Limoges (UNILIM)-CHU Limoges-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu-Université Paris Descartes - Paris 5 (UPD5), Université Pierre et Marie Curie - Paris 6 (UPMC), Immunologie - Immunopathologie - Immunothérapeutique (I3), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Département de Médecine Interne et Pneumologie [Brest] (DMIP - Brest), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), Centre d'Investigation Clinique (CIC - Brest), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Service de dermatologie et allergologie [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département de Biostatistique, Santé Publique et Information Médicale [CHU Pitié-Salpêtrière] (BIOSPIM ), Centre d'études européennes et de politique comparée (CEE), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO)-Université de Brest (UBO), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-CHU Limoges, and Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM)
- Subjects
Anti-Mullerian Hormone ,Endocrinology, Diabetes and Metabolism ,[SDV]Life Sciences [q-bio] ,Clinical Biochemistry ,Biochemistry ,Cohort Studies ,0302 clinical medicine ,Endocrinology ,MESH: Pregnancy ,Pregnancy ,Lupus Erythematosus, Systemic ,Medicine ,MESH : Lupus Erythematosus, Systemic ,MESH: Double-Blind Method ,MESH : Female ,MESH : Immunosuppressive Agents ,MESH: Cohort Studies ,MESH : Cyclophosphamide ,Univariate analysis ,030219 obstetrics & reproductive medicine ,biology ,Anti-Müllerian hormone ,MESH : Adult ,3. Good health ,Premature ovarian failure ,MESH: Premenopause ,Female ,MESH: Immunosuppressive Agents ,Immunosuppressive Agents ,medicine.drug ,Cohort study ,Adult ,medicine.medical_specialty ,Cyclophosphamide ,MESH : Cohort Studies ,Context (language use) ,03 medical and health sciences ,Double-Blind Method ,Internal medicine ,Humans ,MESH : Double-Blind Method ,MESH: Lupus Erythematosus, Systemic ,030203 arthritis & rheumatology ,Lupus erythematosus ,MESH: Humans ,[ SDV ] Life Sciences [q-bio] ,business.industry ,MESH : Anti-Mullerian Hormone ,Biochemistry (medical) ,MESH : Humans ,MESH: Cyclophosphamide ,MESH: Adult ,medicine.disease ,MESH : Pregnancy ,Premenopause ,biology.protein ,MESH: Anti-Mullerian Hormone ,business ,MESH : Premenopause ,MESH: Female - Abstract
Context: Cyclophosphamide is used for renal and major extrarenal involvement in systemic lupus erythematosus (SLE) and is associated with a risk of premature ovarian failure. There are no data available about the relation between anti-Müllerian hormone (AMH) serum levels and the probability of subsequent pregnancy in SLE patients. Objective: We analyzed AMH levels and the probability of pregnancy in SLE women exposed to cyclophosphamide. Design and Setting: We conducted a matched cohort study in referral centers for SLE. Patients: Fifty-six cyclophosphamide-exposed SLE women younger than 40 years of age and 56 control SLE women matched for age within 6 months participated in the study. Main Outcome Measures: AMH was measured in samples from the PLUS study (ClinicalTrials.gov no. NCT00413361). All patients were interviewed in May 2012 regarding their obstetric status. Results: The mean age ± SD of the 112 patients was 31.6 ± 5.8 years. The mean AMH level was low (1.21 ± 1.01 ng/mL) and was significantly lower in patients exposed to cyclophosphamide (P = .03) and in patients older than 30 years (P = .02). During a median follow-up (interval between sampling and the interview) period of 4.2 (range, 2.5–4.8) years, 38 patients sought to become pregnant, and 32 (84.2%) succeeded. In the univariate analysis, the risk of failure was associated with cumulative cyclophosphamide dose (P = .007) and older age (P = .02), but not with AMH. Conclusion: We confirmed that AMH levels are low in SLE patients and decrease significantly with age and cyclophosphamide exposure. Nonetheless, the risk of failure to conceive was low and was predicted by cyclophosphamide exposure and age, but not by AMH levels.
- Published
- 2013
36. Adherence to treatment in systemic lupus erythematosus patients
- Author
-
Gaëlle Guettrot-Imbert, Jacques Pouchot, Nathalie Costedoat-Chalumeau, Véronique Le Guern, Jean-Charles Piette, Donata Marra, Nathalie Morel, Gaëlle Leroux, Université Paris Descartes - Paris 5 (UPD5), Service de médecine interne et centre de référence des maladies rares [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Médecine Interne [CHU HEGP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Centre de référence des syndromes drépanocytaires majeurs, Université de Clermont-Ferrand, Service de Médecine Interne [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de Chirurgie Générale, Viscérale et Endocrinienne [CHU Pitié-Sapêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Centre de référence des syndromes drépanocytaires majeurs, Service de Médecine Interne Clermont Ferrand (MéDECINE INTERNE - CLERMONT-FERRAND), Hopital, CHU Pitié-Salpêtrière [APHP], Service de Chirurgie Générale [CHU Pitié-Salpêtrière], and Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP]
- Subjects
medicine.medical_specialty ,MESH: Antirheumatic Agents ,MESH: Hydroxychloroquine ,MESH: Attitude to Health ,Medication adherence ,Disease ,Therapeutic drug monitoring ,Medication Adherence ,Poor adherence ,03 medical and health sciences ,0302 clinical medicine ,Systemic lupus erythematosus ,Rheumatology ,MESH: Drug Monitoring ,Medicine ,Humans ,Lupus Erythematosus, Systemic ,In patient ,MESH: Lupus Erythematosus, Systemic ,030212 general & internal medicine ,skin and connective tissue diseases ,Intensive care medicine ,030203 arthritis & rheumatology ,MESH: Humans ,medicine.diagnostic_test ,business.industry ,Health advice ,Hydroxychloroquine ,MESH: Medication Adherence ,3. Good health ,Adherence ,Antirheumatic Agents ,Assessment methods ,Physical therapy ,MESH: Biomarkers ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,Drug Monitoring ,business ,Attitude to Health ,Biomarkers ,Flare ,medicine.drug ,Compliance - Abstract
International audience; Adherence is defined as "the extent to which a person's behaviour coincides with medical or health advice." Poor adherence to therapeutic regimens is a common and expensive problem in patients with chronic diseases including systemic lupus erythematosus (SLE) and is associated with a higher risk of flares, morbidity, hospitalisations and poor renal outcome. Non-adherence to the treatment is multifactorial for most patients and varies according to unintentional or intentional patterns. The rates of non-adherence in SLE patients range from 3% to 76% depending on the assessment methods, which are all subject to limitations. Indeed, poor adherence to therapeutic regimens is difficult to evaluate. Two studies have shown that undetectable blood hydroxychloroquine (HCQ) concentration may be a simple, objective and reliable marker of non-adherence in SLE patients. The accurate diagnosis of non-adherence may prevent one from incorrectly interpreting disease manifestations as a lack of response. It may then avoid an unnecessary or even dangerous treatment escalation.
- Published
- 2013
37. Liste des collaborateurs
- Author
-
Amina ABDESSEMED, Zahir AMOURA, Farida AMIOUR, Mathieu ARTIFONI, Brigitte BADER-MEUNIER, Laurent BALLONZOLI, Didier BESSIS, Raphaël BORIE, Éric BRUCKERT, Paul COPPO, Nathalie COSTEDOAT-CHALUMEAU, Marion COUROUGE, Bruno CRESTANI, Claire DAÏEN-IMMEDIATO, Jérôme DE SEZE, Philippe DIEUDÉ, Benoît DUPONT, Marie-Odile DUZANSKI, Alexandra ESPITIA, Camille FRANCES, Bertrand GODEAU, Joëlle GOETZ, Anne GOMPEL, Jacques-Éric GOTTENBERG, Gaëlle GUETTROT-IMBERT, Éric HACHULLA, Gilles HAYEM, Mohamed HAMIDOU, Jean-Sébastien HULOT, René-Louis HUMBEL, Rose-Marie JAVIER, Estibaliz LAZARO, Maëva LEFEBVRE, Véronique LE GUERN, Gaëlle LEROUX, Dan LIPSKER, Alexis MATHIAN, Sylvain MATHIEU, Xavier MARIETTE, Donata MARRA, Olivier MEYER, Jacques MOREL, Sandrine MORELL-DUBOIS, Bruno MOULIN, Antoine NÉEL, Christophe RICHEZ, Jean-Louis PASQUALI, Nathalie PHILIPPI, Jean-Charles PIETTE, Xavier PUECHAL, Christian ROUX, Jean-Hugues SALMON, Patricia SENET, Raphaëlle SEROR, Jean SIBILIA, Philippe SOGNI, Christelle SORDET, Martin SOUBRIER, Géraldine SPRINGINSFELD, Jean-Marie REIMUND, and Stéphanie VIENNOT
- Published
- 2013
38. Comment gérer la grossesse et l'allaitement d'une patiente lupique et/ou ayant un syndrome des antiphospholipides ?
- Author
-
N. Costedoat-Chalumeau and Gaëlle Guettrot-Imbert
- Subjects
business.industry ,Medicine ,business - Published
- 2013
39. Evaluation of the severe preeclampsia classification criterion for antiphospholipid syndrome in a study of 40 patients
- Author
-
Maddalena Larosa, Véronique Le Guern, Nathalie Morel, Mériem Belhocine, Amelia Ruffatti, Nicolas Martin Silva, Romain Paule, Luc Mouthon, Michel Dreyfus, Jean-Charles Piette, Odile Souchaud-Debouverie, Catherine Deneux-Tharaux, Gaelle Guettrot-Imbert, Vassilis Tsatsaris, Emmanuelle Pannier-Metzger, Anne Murarasu, Andrea Doria, and Nathalie Costedoat-Chalumeau
- Subjects
Antiphospholipid syndrome ,Systemic lupus erythematosus ,Thrombosis ,Pregnancy ,Severe preeclampsia ,Classification criteria ,Diseases of the musculoskeletal system ,RC925-935 - Abstract
Abstract Background The criteria for antiphospholipid syndrome (APS) include severe preeclampsia and/or placental insufficiency leading to preterm delivery before 34 weeks of gestation, but this APS manifestation has been rarely studied. Thus, we report a series of severe preeclampsia occurred in patients with APS. Methods We retrospectively analysed data of women with APS (Sydney criteria) who experienced severe preeclampsia with delivery before 34 weeks’ gestation between 2000 and 2017 at five French internal medicine departments and one Italian rheumatology unit. Results The 40 women had a mean age of 30.5 ± 4.6 years at their first episode of preeclampsia; 21 were nulligravid (52.5%), 12 (30%) had already been diagnosed with APS, and 21 (52.5%) had a triple-positive antiphospholipid (aPL) antibody test. Preeclampsia occurred at a median gestational age of 25.5 weeks (IQR 23-29). It was associated with HELLP in 18 cases (45%), eclampsia in 6 (15%), placental abruption in 3 (7.5%), catastrophic APS in 3 (7.5%), and foetal and neonatal death in 11 and 15 cases. Overall, 14 (35%) children survived, born at a median gestational age of 31 weeks. Among other APS criteria, 16 women (40%) experienced at least one thrombosis, 17 (42.5%) an intrauterine foetal death, and 19 (47.5%) at least one episode of HELLP during follow-up (median 5 years, IQR = 2-8). None had three or more consecutive miscarriages. Notably, 12 women (30%) had systemic lupus erythematosus. Conclusions Severe preeclampsia led to high mortality in the offspring. Almost half of these women experienced other APS features, but not three consecutive miscarriages.
- Published
- 2021
- Full Text
- View/download PDF
40. [IgG4 related disease]
- Author
-
Marion, Hermet, Jean-Louis, Kémény, Gaëlle, Guettrot-Imbert, Isabelle, Delèvaux, Olivier, Aumaître, and Marc, André
- Subjects
Pancreatitis ,Concept Formation ,Immunoglobulin G ,Humans ,Fibrosis ,Models, Biological ,Pancreas ,Autoimmune Diseases - Abstract
IgG4 related disease (IgG4 RD) was first reported as autoimmune pancreatitis then it was established as a systemic disorder characterised by high blood level of IgG4 and fibrosis with rich plasmocytes IgG4+ in almost all organs. IgG4 RD is very sensitive to corticosteroid therapy. IgG4 RD has a high prevalence in eastern countries. Numerous articles on this topic are published and new diagnostic criteria are regularly established. The autoimmune or allergic mechanism of IgG4 RD is still a matter of debate. Interestingly, IgG4 subclass of antibody has anti-inflammatory features. IgG4 RD is not yet very well characterised in western countries. Whether IgG4 is involved in IgG4 RD, pathophysiology is to be defined. IgG4 RD spontaneously regresses in some cases so indications of treatment are not already well clear.
- Published
- 2011
41. La iatrogénie n’est jamais loin : à propos d’une entéropathie exsudative sous-olmesartan
- Author
-
A. Mania, M. Hermet, A. Bardy, O. Aumaître, P. Letertre-Gibert, Gaëlle Guettrot-Imbert, and M. André
- Subjects
business.industry ,Gastroenterology ,Internal Medicine ,Medicine ,business - Published
- 2014
42. A new presentation of neonatal lupus: 5 cases of isolated mild endocardial fibroelastosis associated with maternal Anti-SSA/Ro and Anti-SSB/La antibodies
- Author
-
Gaëlle Leroux, Zahir Amoura, Patrice Cacoub, Camille Francès, Olivier Thiebaugeorges, Elisabeth Villain, Gaëlle Guettrot-Imbert, Laurent Fermont, Bernard Foliguet, Laurence Cohen, Nathalie Costedoat-Chalumeau, and Jean-Charles Piette
- Subjects
Adult ,medicine.medical_specialty ,Pathology ,Immunology ,Autopsy ,Gastroenterology ,Rheumatology ,Pregnancy ,Internal medicine ,Prenatal Diagnosis ,medicine ,Immunology and Allergy ,Humans ,Lupus Erythematosus, Systemic ,Neonatal lupus erythematosus ,Immunoassay ,Fetus ,business.industry ,Dilated cardiomyopathy ,Endocardial fibroelastosis ,Endocardial Fibroelastosis ,medicine.disease ,In utero ,Antibodies, Antinuclear ,Betamethasone ,Female ,business ,medicine.drug ,Anti-SSA/Ro autoantibodies - Abstract
Objective.Maternal anti-SSA/Ro or anti-SSB/La antibodies are associated with neonatal lupus erythematosus syndrome (NLES), especially congenital heart block (CHB), which may be associated with severe endocardial fibroelastosis (EFE) and dilated cardiomyopathy (DCM). A few reports have described severe EFE without CHB associated with anti-SSA/Ro antibodies, with a poor prognosis. EFE has also been observed in biopsies of DCM that had been considered idiopathic. These points, considered in association with 5 unusual cases of mild EFE, led us to consider the relationship between underrecognized cases of isolated autoantibody-associated EFE and DCM that had been considered idiopathic.Methods.We analyzed 5 cases of EFE diagnosed in utero (n = 4) or after birth (n = 1). In 3 cases, maternal antibody status was discovered because of the EFE diagnosis.Results.Endomyocardial hyperechogenicity predominated in the left atrium (n = 3) and mitral annulus (n = 3). No left-heart dysfunction was observed. Two mothers were treated with betamethasone. One mother chose to have a therapeutic abortion, and EFE was confirmed at autopsy. Electrocardiograms at birth (n = 4) did not show CHB. Other manifestations of NLES were present in all cases. One child had right ventricular hypoplasia and underwent a partial cavopulmonary anastomosis. At last followup (4–7 yrs), the other 3 children had normal heart function, and echocardiography showed a normal heart (n = 2) or mild persistent EFE (n = 1).Conclusion.Middle-term prognosis of isolated autoantibody-associated EFE may be better than previously reported, although the longterm prognosis remains unknown. We hypothesize that a fetal insult can lead to DCM.
- Published
- 2010
43. Le syndrome d’inflammation orbitaire idiopathique doit rester un diagnostic d’exclusion
- Author
-
H. Nezzar, L. Olagne, O. Aumaître, M. André, Gaëlle Guettrot-Imbert, Jean-Louis Kémény, M. Hermet, and A. Bardy
- Subjects
business.industry ,Gastroenterology ,Internal Medicine ,Medicine ,business - Published
- 2013
44. Adénite granulomateuse : ne pas oublier la syphilis !
- Author
-
M. André, A. Bardy, N. Mrozek, L. Olagne, M. Hermet, L. Duron, Gaëlle Guettrot-Imbert, M. Russier, and O. Aumaître
- Subjects
business.industry ,Gastroenterology ,Internal Medicine ,Medicine ,business - Published
- 2013
45. Gammapathie monoclonale associée à une pseudohypofibrinogénémie
- Author
-
M. Hermet, A.-F. Serre Sapin, M. André, A. Bardy, Gaëlle Guettrot-Imbert, O. Aumaître, and P. Smets
- Subjects
Gastroenterology ,Internal Medicine - Published
- 2013
46. Letter by Guettrot-Imbert et al Regarding Article, 'Early Diagnosis and Treatment of Atrioventricular Block in the Fetus Exposed to Maternal Anti-SSA/Ro-SSB/La Antibodies'
- Author
-
Zahir Amoura, Gaëlle Guettrot-Imbert, and Nathalie Costedoat-Chalumeau
- Subjects
Fetus ,Pediatrics ,medicine.medical_specialty ,biology ,business.industry ,Incidence (epidemiology) ,medicine.disease ,Congenital heart block ,Physiology (medical) ,biology.protein ,Medicine ,Antibody ,Cardiology and Cardiovascular Medicine ,business ,Pathological ,Atrioventricular block ,Anti-SSA/Ro autoantibodies - Abstract
To the Editor: We read with great interest the article by Rein et al1 that describes how fetal kinetocardiogram can accurately detect first-degree congenital heart block (CHB) in fetuses exposed to maternal anti-SSA/Ro and/or anti-SSB/La antibodies. We question, however, whether these cases of first-degree CHB were all necessarily pathological and consequently in need of treatment. The incidence of the first-degree CHB was 9% (6 affected fetuses among 70), which is much …
- Published
- 2009
47. Un purpura thrombopénique immunologique paranéoplasique
- Author
-
P. Smets, M. André, M. Hermet, Gaëlle Guettrot-Imbert, and O. Aumaître
- Subjects
business.industry ,Gastroenterology ,Internal Medicine ,Medicine ,business - Published
- 2013
48. Bilan étiologique des thromboses veineuses rénales : à propos d’une étude rétrospective monocentrique de 75 patients
- Author
-
Gaëlle Guettrot-Imbert, M. André, P. Chabrot, E. Alexa, Louis Boyer, Marc Ruivard, M. Hermet, I. Delèvaux, and O. Aumaître
- Subjects
Gastroenterology ,Internal Medicine - Published
- 2012
49. TREX1 est-il impliqué dans les manifestations neuropsychiatriques du lupus systémique ? Étude du génotype sur une cohorte française
- Author
-
Z. Amoura, M. André, O. Aumaître, N. Costedoat-Chalumeau, J.C. Piette, J.-S. Hullot, A. Dion, P. Blanc, Isabelle Creveaux, Gaëlle Guettrot-Imbert, and C. Nachury
- Subjects
Gastroenterology ,Internal Medicine ,Biology - Published
- 2012
50. Adénopathie prétragienne : pensez à Bartonella henselae !
- Author
-
C. Makarawiez, M. Hermet, Gaëlle Guettrot-Imbert, A.-S. Resseguier, I. Delèvaux, O. Aumaître, and M. André
- Subjects
Bartonella henselae ,biology ,business.industry ,Gastroenterology ,Internal Medicine ,Medicine ,biology.organism_classification ,business ,Virology - Published
- 2012
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.